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1. Introduction 
Osteoporosis can be classified into two big categories, clinical osteoporosis and 
densitometric osteoporosis. Clinical osteoporosis involves a fragility fracture, and no 
densitometry is needed to start treatment. Densitometric osteoporosis is defined by means 
of a bone mineral density assessment. Treatment should be considered depending on the 
global fracture risk, and taking the densitometric results into account.  
The first step in the pharmacological treatment of osteoporosis is to identify whether it is a 
primary disease or whether the bone mass loss is secondary to another disease. In the case of a 
secondary osteoporosis, treatment of the primary disease is the most important step. 
Pharmacological treatment should then be considered if the fracture risk is too high. The 
purpose of pharmacological treatment in osteoporosis is to reduce the risk of fracture. 
According to the World Health Organization’s more than half of the patients suffering a 
fragility fracture do not have densitometric osteoporosis. (Siris et al., 2004) When any 
medication is started for osteoporosis treatment it must be remembered that this illness will 
require treatment for a long time and that the drug has to be given in conjunction with advise 
regarding lifestyle changes. It is therefore imperative to evaluate and make decisions based on 
issues such as cost, evaluation of cost-efficiency, and patient adaptability to drug safety. 
2. Antiresorptives 
2.1 Calcitonin 
Calcitonin is a 32 amino acid polypeptide. It binds to osteoclasts and inhibits bone 
resorption. Calcitonins from many species are effective in humans, but salmon calcitonin is 
the most widely used. It is extremely potent in humans due to its higher affinity (forty times 
that of human calcitonin) for the human calcitonin receptor. The only other calcitonin 
clinically used is human calcitonin, less potent but also less antigenic than salmon calcitonin. 
(Carstens & Feinblatt, 1991) It can be administered by intramuscular, intravenous or nasal 
route. The bioavailability of nasal salmon calcitonin is only about 25 percent that of 
intramuscular calcitonin; thus, the biological effect of 50 international units (IU) of 
intramuscular salmon calcitonin is comparable to that of 200 IU of nasal salmon calcitonin. 
(Overgaard et al., 1991) 
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2.1.1 Clinical data 
There is evidence that calcitonin is effective in the treatment of established osteoporosis. In 
one study of calcitonin in osteoporosis, 208 elderly osteopenic women were treated with 
calcium and either intranasal placebo, or 50, 100, or 200 IU of daily salmon calcitonin for two 
years. Mean spine bone mineral density (BMD) was increased by salmon calcitonin in a 
dose-dependent manner, and a maximum effect was seen with the 200 IU dose. (Overgaard 
et al., 1992) 
The largest clinical trial with calcitonin for the treatment of osteoporosis was a five-year trial 
comprising 1,255 women with a lumbar spine T score of <-2 and at least one vertebral 
fracture. They were randomly assigned to placebo or 100, 200, or 400 IU of intranasal 
calcitonin per day. There was a small increase in spine BMD (1% to 1.5%) in all groups. The 
risk of vertebral fracture was significantly lower than placebo only in the group taking 200 
IU per day, and the risk of non-vertebral fractures was significantly lower than placebo only 
in the group taking 100 IU per day. Thus, the beneficial effect of nasal calcitonin on vertebral 
BMD and vertebral fracture risk was small and inconsistent. (Chesnut et al., 2000) 
Nowadays calcitonin is not a current therapy for osteoporosis. It has been displaced by 
other treatments. However, one beneficial short-term effect of calcitonin therapy is pain 
reduction in patients who have sustained a fracture. In one study, looking for pain effect of 
calcitonin, 56 osteoporotic women who sustained an atraumatic vertebral fracture were 
randomly assigned to treatment with placebo or 100 IU of intramuscular salmon calcitonin 
daily for two weeks. Mean pain scores and analgesic consumption in the calcitonin group 
were significantly lower than in the placebo group by the fourth day. Similar benefits on 
bone pain have been observed in several other small, randomized trials of parental and 
nasal calcitonin. The ability to relieve pain may represent a truly distinguishing feature from 
other drugs used in the treatment of osteoporosis and maybe today it is one of its main 
indications. (Lyritis et al., 1991) 
2.1.2 Adverse effects 
The most frequent adverse effects of calcitonin appear during or shortly after its parenteral 
administration: digestive disorders, nausea, vomiting, abdominal pains, diarrhea, 
vasomotor disorders or facial flushing among others. Allergy to calcitonin is possible but 
exceptional. Thus, calcitonin may be the antiresorptive agent of choice in patients with pain 
from an acute osteoporotic fracture. Why pain relief occurs is not well understood; one 
possibility is a rise in endorphin levels induced by calcitonin. 
2.2 Hormonal replacement therapy (HRT) 
The HRT is a treatment option that includes different estrogen doses, in combination, or not, 
with progestagens. Hormonal replacement therapy is described in detail in another chapter. 
Therefore, in this chapter we are just going to make a review of the antifracture efficacy of 
HRT along with the safety data from different meta-analysis, systematic reviews and clinical 
guides.  
2.2.1 Hormone replacement therapy (HRT) for fracture prevention 
The estimations of fracture risk, derived from the principal cohort studies of 
postmenopausal women, using HRT for long periods of time, show a significant vertebral 
fracture risk reduction (RR=0.6; CI 95%: 0.36 to 0.99) and wrist fracture risk reduction 
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(RR=0.39; CI 95%: 0.24 to 0.64), but a non-significant hip fracture risk reduction (RR=0.64; CI 
95%: 0.32 to 1.04). The WHI study (Women's Health Initiative), a randomized clinical trial 
(RCT) that evaluated postmenopausal women randomized to combined HRT (combined 
equine estrogen 0.625 mg daily plus medroxyprogesterone 2.5 mg daily) or placebo, 
demonstrated, after 5.2 years of treatment, a hip fracture risk reduction of 34% (hazard ratio 
[HR]=0.66; CI 95%: 0.45 to 0.98), of clinical vertebral fractures of 34% (HR=0.66; CI 95%: 0.44 
to 0.98) and a reduction in any fracture of 24% (HR=0.76; CI 95%: 0.69 to 0.85). (Rossouw et 
al., 2002; Cauley et al., 2003) In the same study, the branch using estrogen alone showed 
similar results, but it was suspended due to an unfavorable risk benefit ratio. (Anderson et 
al., 2004) In two meta-analysis of RCTs a reduction of 27% (RR=0.73; CI 95%: 0.56 to 0.94) in 
non-vertebral fractures and a tendency towards the decrease of vertebral fractures (RR=0.66; 
CI 95%: 0.41 to 1.07) was described. (MacLean et al., 2008) Nevertheless, from the HERS (The 
Heart and Estrogen + Progestin Replacement Study) RCT and from the cohort followed, the 
HERS II study (Hulley et al., 1998), no reduction of the risk of hip fractures or of other 
locations (RR=1.04; CI 95%: 0.87 to 1.25) in women with cardiovascular disease history, 
could be demonstrated. (Cauley et al., 2001) 
Another meta-analysis, which included information from two publications of the WHI 
study (women with and without osteoporosis, without DMO measurements) found a 
reduction of 25% of the relative risk of non-vertebral fractures (RR=0.75; CI 95%: 0.70 to 0.81) 
in a sample of 31,333 patients followed up for a maximum of 7 years and a 36% relative risk 
reduction for hip fractures (RR=0.64; CI 95%: 0.49 to 0.84) in a sample of 27,347 patients. 
(Liberman et al., 2006) The British National Institute of Health and Clinical Excellence 
presented a meta-analysis of RCTs on the efficacy of HRT (with estrogen alone or combined) 
vs. placebo / not treatment in postmenopausal women or with surgical menopause. 
(National Institute for Clinical Excellence [NICE], 2008) The results were presented by 
fracture location and specified the RCT used for the estimation of the relative risk. The 
results are summarized in table 1.  
2.2.2 Safety 
2.2.2.1 Vascular illness 
A systematic review of five RCTs, studying HRT with estrogen and two with combined 
HRT estrogen plus progesterone, did not demonstrate significant differences in the 
incidence of acute coronary events (including acute myocardial infarction) between the 
group of intervention and the control group. (MacLean et al., 2008) Two of the essays with 
estrogen and two of combined therapy (estrogen plus progesterone) that reported the 
incidence of death of cardiac origin did not demonstrate significant differences between the 
intervention group and control group. Combined results of three essays comparing 
estrogenic therapy with placebo (Anderson et al., 2004; Mosekilde et al., 2000; Cherry et al., 
2002) presented an odds ratio (OR) of 1.34 (IC 95%: 1.07 to 1.68) for cerebral vascular events. 
The combined results of the essays that compared combined therapy estrogen plus 
progesterone with placebo (Rossouw et al., 2002; Hulley et al., 1998), demonstrated a higher 
risk of ictus (OR=1.28; CI 95%: 1.05 to 1.57) in the intervention group. Of 4 systematic 
reviews of observational studies in women receiving HRT (Stampfer et al., 1991; Grady et 
al., 2002; Barrett-Connor, 1992; Humphrey et al., 2002), three demonstrated an important 
reduction in the global risk of mortality for acute coronary events. The most recent 
systematic review, that controlled selection bias of inclusion and analysis, did not show any 
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association between the THS and the incidence, and mortality of acute coronary events. 
(Humphrey et al., 2002) 
The WHI primary prevention study showed a significant increase in the risk of acute 
coronary events (41%), beginning the second year of treatment (29 cases in the treatment 
group, compared with 21 cases for 10.000 women/year in the general population). 
(Rossouw et al., 2002) This increase was higher in non-mortal coronary events (RR=1.50; CI 
95%: 1.08 to 2.08) than in the mortal coronary events (RR=1.20; CI 95%: 0.58 to 2.50). The 
RCTs of HRT with estrogens alone, in primary prevention as well as in secondary 
prevention, did not show any benefit on the cerebrovascular illness. (Viscoli et al., 2001) The 
group of the WHI study with estrogen also showed an increase in the risk of 
cerebrovascular accidents. (Anderson et al., 2004) 
 
Fracture Location Nr of RCTs n RESULTS References 
Vertebral fracture 4 RCTs 11,842
RR=0.55; CI 95%: 
0.46 to 0.66 
(Wimalawansa, 1998; 
Mosekilde et al., 2000; 
Anderson et al., 1997; 
Lufkin et al., 1992) 
Non-vertebral fracture 3 RCTs 11,774
RR=0.73; CI 95%: 
0.65 to 0.81 
(Wimalawansa, 1998; 
Anderson et al., 2003; 
Mosekilde et al., 2000) 
Hip fracture 2 RCTs 11,745
RR=0.63; CI 95%: 
0.42 to 0.93 
(Anderson et al., 2003; 
Mosekilde et al., 2000) 
Any type of fracture 3 RCTs 11,556
RR=0.70; CI 95%: 
0.63 to 0.78 
(Anderson et al., 2003; 
Herrington et al., 2000; 
Ravn et al., 1999) 
Table 1. Relative risk of fractures in meta-analysis from the NICE 
2.2.2.2 Venous thrombotic events 
In a systematic review, McLean et al., reported that estrogen treated patients present a 
higher risk of major venous thromboembolic events (OR=1.36; CI 95%: 1.01 to 1.86) 
compared to the placebo group. (MacLean et al., 2008) Another systematic review 
evaluating the effect of the HRT (estrogen with or without progestagens) included 12 
studies (3 RCTs, 8 case-control studies and 1 cohort study) and showed an increase in the 
risk of thromboembolism (RR=2.14; CI 95%: 1.64 to 2.81). This risk is higher in the first two 
years of treatment and it is dose dependant. (Miller et al., 2002) The HERS study for 
secondary prevention showed an increase in the risk of thromboembolism in women with 
cardiovascular illness. (Hulley et al., 1998; Grady et al., 2002)  
2.2.2.3 Breast cancer 
A systematic review of 4 RCTs demonstrated that patients treated with estrogens alone 
present lower risk of breast cancer (OR=0.79; CI 95%: 0.66 to 0.93) compared to placebo. 
(MacLean et al., 2008) On the contrary, patients treated with estrogen and progestin present 
a higher risk of breast cancer (OR=1.28; CI 95%: 1.03 to 1.60) compared to placebo. (Rossouw 
et al., 2002; Hulley et al., 1998; Lufkin et al., 1992)  
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The combined HRT group of the WHI study, showed an increase in the risk of invasive 
breast cancer. (Rossouw et al., 2002) This increase took place after the fourth year of 
treatment (RR=1.26; CI 95 %: 1.0 to 1.59), with a tendency to increase according to the 
duration of the treatment (38 cases compared with 30 for 10,000 women/year). The patients 
in the treatment group were diagnosed in more advanced stages. No significant differences 
were found for the in situ carcinoma. (Chlebowski et al., 2003) Moreover, other studies have 
demonstrated that both the sequential and the continuous administration of the 
progestagens, collaborate to increase breast cancer. (Li et al., 2003) 
2.2.2.4 Endometrial cancer 
The administration of isolated estrogen increases the risk of developing endometrial 
hyperplasia and cancer. (Lethaby et al., 2004; Nelson, 2004) A meta-analysis including 29 
observational studies showed a significant increase in the endometrial cancer risk with or 
without combined estrogens (RR=2.3; CI 95%: 2.1 to 2.5). (Grady et al., 1995) This risk is 
proportional to the duration of the treatment and remains elevated for up to 5 years or more 
after stopping treatment. In addition, an increase in endometrial cancer mortality was 
observed, but it was a non-significant increase (RR=2.7; CI 95 %: 0.9 to 8.0). The combined 
HRT group of the WHI study and its continuation for secondary prevention (HERS II) 
showed a relative risk of endometrial cancer of 1.58 without reaching statistical significance 
(IC 95%: 0.77 to 3.24). (Menopause and post menopause workgroup, 2004) 
2.2.2.5 Ovarian cancer 
In a systematic review of several case-control studies no association could be found between 
HRT and ovarian cancer. (Coughlin et al., 2000) In contrast, more recent systematic reviews 
of observational studies confirm the increase in the risk of ovarian cancer in women 
receiving treatment, especially long-term treatment (more than 10 years). (Garg et al., 1998; 
Negri et al., 1999) Two cohort studies of postmenopausal women treated for more than 10 
years confirm this risk increase (RR=2.2; CI 95%: 1.53 to 3.17), as well as the mortality risk 
(RR=1.59; CI 95%: 1.13 to 2.25). (Lacey et al., 2002; Rodriguez et al., 2001) The combined HRT 
group of the WHI study also showed a non-significant increase in the risk of ovarian cancer 
(RR=1.58; CI 95 %: 0.77 to 3.24). (Anderson et al., 2003) 
In summary, HRT is effective for the treatment of postmenopausal osteoporosis and the 
reduction of fracture risk. In spite of this, it is not advisable to use HRT (combined estrogen 
and progestagens) for more than 5 years due to the potential risks associated with the 
treatment of an equivalent dose of 50 picograms of estradiol per day. When HRT is 
indicated, it has to be prescribed at low doses (equivalent to estrogen transdermal patches of 
25 mcg) and only if strictly necessary, higher doses. Estrogens and progestagens are 
recommended only in women with intact uteri. The progestagen dose must be calculated 
according to the estrogen dose. In those cases where a hysterectomy was performed due to 
endometrial cancer, HRT must not combine estrogen and progestagens. Continuous 
combined HRT must not be started until after one year of menopause.  
2.3 Selective estrogen receptor modulators (SERMs) 
So far two estrogen receptors have been described, alpha (ER) and beta (ER), which are at 
different levels and locations in different body tissues. The ER are mainly in the developing 
spongy bone, while ER are concentrated more on the cortical bone. In addition, these 
receptors have differences in their structure and function, which would explain other effects 
of estrogen deficiency as vasomotor symptoms or alterations in the lipid profile.  
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The selective estrogen receptor modulators are drugs with selective effects on the estrogen 
receptor. They can act as estrogen receptor agonists in some tissues while acting as estrogen 
receptor antagonists in others. SERMs embrace diverse molecules that lack the steroid 
structure of estrogens, but own a tertiary structure that allows them to bind to ER and/or 
ER with different potency. In contrast to estrogens and estrogen receptor agonists, these 
are partial agonists/antagonists. Due to their selective estrogen-agonist properties on 
different tissues, SERMs may be indicated for the prevention or treatment of diseases caused 
by estrogen deficiency, like osteoporosis, without some of the adverse effects of estrogens. 
In addition, due to their selective properties in the breast (estrogen receptor antagonists), 
SERMs can be also utilized to prevent or treat breast cancer, where estrogen-agonistic 
activity is not wanted.  
2.3.1 Differences between SERMs 
Currently there are two types of SERMs that are differentiated by their chemical structure: 
triphenylethylene derivatives, such as tamoxifen and toremifene, and a benzothiophene 
derivative, raloxifene. The first two are used for the treatment of breast cancer while 
raloxifene is indicated for the prevention and treatment of osteoporosis. All have been 
associated with an increased incidence of pulmonary thromboembolism and with the onset 
of hot flushes but they have a beneficial effect on the lipid profile.  
Tamoxifen is not indicated for the treatment of osteoporosis due to increased incidence of 
endometrial cancer associated with prolonged treatment and the weak effect of this drug on 
bone that is not maintained over time. The results of the studies that evaluated the effect of 
tamoxifen on fracture risk were contradictory.  
The SERMs differ significantly in terms of tissue specificity. Bazedoxifene seems to have less 
effect on the uterus than estradiol and raloxifene in animal experiments due to lower 
estrogen receptor alpha agonistic effects. Tamoxifen and toremifene are used to treat breast 
cancer. Raloxifene is indicated for the treatment and prevention of osteoporosis and for the 
prevention of breast cancer. Besides the SERMs described in this review, other new SERMS 
have had clinical trials suspended prematurely: levormeloxifene, for causing urinary 
incontinence and uterine prolapse, arzoxifene for lacking effectiveness, and idoxifene, for 
resulting in increased endometrial thickness on ultrasonography but without significant 
histological abnormality. 
2.4 Raloxifene 
Raloxifene has estrogenic activity in bone and other systems but not in reproductive tissue. 
In ovariectomized animals, raloxifene preserves bone density, lowers serum total 
cholesterol, and inhibits aortic cholesterol accumulation, without causing endometrial 
hyperplasia. The mechanism of selectivity of raloxifene is not fully understood. There are 
studies that suggest that raloxifene has different effects than estradiol at the estrogen 
receptor. It also seems to have a different modulation in DNA response.  
Several studies have demonstrated the effectiveness of raloxifene in the preservation of bone 
in early postmenopause. In a meta-analysis of seven trials (four treatment and three 
prevention trials) examining the effects of raloxifene versus placebo on bone mineral 
density, raloxifene increased bone mineral density of the lumbar spine after two years of 
treatment. (Cranney et al., 2002) A study with 601 women, five years after menopause, that 
received a daily treatment with 30, 60 or 150 mg of raloxifene for two years, showed an 
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increase in bone mineral density in spine and hip, while the placebo was associated with 
reduced bone mineral density at the same sites. (Delmas et al., 1997) Compared to placebo, 
the average change in BMD with 60 mg of raloxifene was 2.4% at the spine and 2.4% at the 
total hip (p <0.001 vs placebo). However, in two placebo-controlled trials with 145 5-year 
postmenopausal women 60 years or younger, treatment with raloxifene for three years 
showed a minor effect on spine and hip BMD. (Johnston et al., 2000) The change in BMD of 
the spine at three years was -1.32% with placebo, 0.71% with 30 mg of raloxifene, 1.28% with 
60 mg raloxifene and 1.2% with 150 mg of raloxifene. Similar changes in hip BMD were 
observed in the respective treatment groups. In another analysis two studies involving 328 
women with a mean age of 55 years and five years after menopause, treatment for five years 
with 60 mg of raloxifene was associated with preservation of BMD and a reduced risk of 
osteoporosis compared with the placebo group. The treatment with raloxifene compared to 
placebo showed an average increase in BMD of 2.8% at the lumbar spine and 2.6% at the hip 
(in both p <0.001). (Jolly et al., 2003) 
Raloxifene has shown to be effective in reducing the risk of invasive breast cancer in older 
women. Postmenopausal women with low bone mass and osteoporosis were studied in a 
trial named Multiple Outcomes of Raloxifene Evaluation (MORE, n=7,705) and its 
complementary study, called the Continuing Outcomes Relevant to Evista (CORE, n=4,011). 
(Burshell et al., 2008) In this study, women had an average age of 65 years (group with low 
bone mass) and 68 years (group with osteoporosis) and were followed for eight years. 
Regarding fractures, raloxifene reduced the risk of vertebral fracture; however, it did not 
show a reduction in non-vertebral fractures. Moreover, in a meta-analysis of RCTs 
comparing raloxifene to placebo, raloxifene consistently reduced the risk of vertebral 
fractures in postmenopausal women (OR=0.6; CI 95%: 0.5-0.7).  
In the MORE trial, a subset of 6,828 of the women had lumbar spine x-rays at baseline and 
after 36 months of treatment. Among the women receiving 60 mg and 120 mg raloxifene 
new vertebral fractures were observed in 6.6% and 5.4%, respectively, compared with 10.1% 
in the placebo group. The risk of non-vertebral fracture was similar in the three groups. 
After four years of raloxifene treatment (60 mg per day), the cumulative relative risk of one 
or more vertebral fractures was 0.64 (IC 95%: 0.53 - 0.76), compared with placebo. 
Compared with placebo, treatment with 60 mg of raloxifene was associated with a reduction of 
65 to 78% in the incidence of invasive breast cancer and breast invasive cancer with positive 
estrogen receptor (both p <0.05). Therefore, the FDA approved raloxifene to reduce the risk of 
invasive breast cancer in postmenopausal women at high risk. (Barrett-Connor et al., 2006) 
2.4.1 Combination therapy 
The combination of alendronate and raloxifene resulted in a greater increase in BMD when 
compared with either drug alone. (Johnell et al., 2002) However, the benefit of combined 
versus monotherapy for fracture reduction is unknown and there are additional costs and 
side effects of taking two agents. As explained previously, some trials have reported 
that raloxifene (either taken concurrently or prior to PTH) does not suppress the BMD 
response to PTH as much as alendronate. 
2.4.2 Adverse events 
Several adverse events are associated with raloxifene. In the MORE and CORE studies an 
association between raloxifene and a 1.7 times increased risk of thromboembolism (TE), 
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compared with placebo, was observed (95% CI: 0.93-3.14; risk difference total of 0.9/1,000 
women-years). (Martino et al., 2005) In a meta-analysis of nine studies, therapy 
with raloxifene was associated with an increase in the risk of deep venous thrombosis and 
pulmonary embolism (OR=1.5; CI 95%: 1.1-2.1 and OR=1.9; 95% CI: 1.0-3.5, respectively). 
(Adomaityte et al., 2008) 
In the RUTH study (Raloxifene Use for The Heart), which included 10,101 postmenopausal 
women with coronary heart disease and an average age of 68 years, there was an association 
between Raloxifene and an increased risk of fatal stroke (HR=1.49; 95% CI: 1.00-2.24, an 
increase in the absolute risk of 0.7/1,000 women-years) and thromboembolism (HR=1.44; 
95% CI: 1.06-1.95, an increase absolute risk of 1.2/1,000 women-years) compared with 
placebo. There was no increased risk of myocardial infarction or other coronary events in 
the RUTH study. However, as observed with thromboembolism and pulmonary embolism, 
the results of a recent analysis in a subgroup of the study showed an effect of age on 
incidence of coronary events, among women 60 years old or younger, the incidence of 
coronary events was significantly lower with raloxifene (50 cases), compared with the 
placebo group (84 cases; HR=0.59; 95% CI: 0.41 to 0.83, p=0.003). Raloxifene was also 
associated with an increase in hot flushes, particularly in women with new onset 
menopause. In MORE and CORE trials, 12.6% of women receiving raloxifene had hot 
flushes, compared with 6.9% in the placebo group (p<0.0001). (Collins et al., 2009) 
In conclusion, raloxifene offers an alternative in the treatment of osteoporosis in selected 
patients. Its profile regarding heart disease and breast cancer is good but it should be 
carefully considered especially due to the high risk of venous thrombosis. 
2.5 Bazedoxifene 
Bazedoxifene is a novel, non-steroidal, indole based SERM that was developed using a 
rigorous preclinical screening process designed to select therapies with favorable effects on 
bone and lipid profiles while reducing the stimulation of uterus or breast tissue. (Komm et al. 
2005; Komm & Lyttle, 2001) It is a third-generation SERM after the first generation tamoxifene, 
and the second-generation raloxifene. (Bazedoxifene: bazedoxifene acetate, 2008) Significant 
differences have been shown between the generations in terms of effects especially on the 
uterus and the breast tissue. (Vogel et al., 2006) It was developed using raloxifene as a template 
with the benzothiophene core substituted by an indole ring. (Gruber & Gruber 2004) 
2.5.1 Pharmacokinetics and pharmacodynamics 
Bazedoxifene is quickly absorbed with a t-max of approximately 2 hours and displays a 
linear increase in plasma concentrations after single doses from 0.5 mg up to 120 mg. 
(Chandrasekaran et al., 2009) It is highly bound (95.8% to 99.3%) to plasma proteins in vitro 
and it is extensively metabolized in women. Glucuronidation is the most important 
metabolic pathway. Slight or no cytochrome P450-mediated metabolism is apparent. 
Bazedoxifene-5-glucuronide is the major circulating metabolite and the concentrations of 
this glucuronide are approximately 10-fold higher than those of non-metabolized active 
substance in plasma. Bazedoxifene is excreted principally by feces and has a half-life of 
approximately 30 hours. Steady-state concentrations are achieved by the second week of 
once-daily administration. (Biskobing 2007; Shen et al., 2010) To study the bioavailability of 
bazedoxifene two oral formulations, a 10 mg tablet and two 5 mg capsules, and a 3 mg IV 
formulation were given to 18 postmenopausal women in a 3-way crossover design. Blood 
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was collected for 168 hours after each dose. The bioavailabilty of bazedoxifene was 6.2% for 
both oral formulations. (Patat et al., 2003) Finally, a study evaluated the longer-term 
pharmacokinetics of multiple doses of bazedoxifene. In a randomized, crossover study 23 
postmenopausal women were given multiple doses of bazedoxifene (5, 20, 40 mg) for 14 
days. Maximum concentration was achieved in 1–2 hours and t½ was approximately 28 
hours. Protein binding was greater than 99%. Steady state concentrations were achieved by 
day 7. (Ermer et al., 2003) 
2.5.2 Bazedoxifene in humans 
Human studies with bazedoxifene have demonstrated a decreased thickness of the 
endometrium at doses of 30 to 40 mg/day compared to placebo or conjugated estrogen plus 
medroxyprogesterone (mean ± standard error of the mean increase after 168 days: 0.04 ± 
0.12 mm for 30 mg, 0.12 ± 0.11 mm for 40 mg, 0.58 ± 0.21 mm for placebo, and 1.60 ± 0.23 
mm for conjugated estrogen plus medroxyprogesterone acetate). (Ronkin et al., 2005) In a 
phase 2 study of healthy postmenopausal women, daily oral doses of bazedoxifene 2.5, 5.0, 
10, 20, 30, or 40 mg were generally well tolerated and did not stimulate the endometrium. 
Furthermore, bazedoxifene 30 and 40 mg caused significantly smaller increases in 
endometrial thickness and significantly reduced the incidence of uterine bleeding compared 
with placebo. In a 2-year phase 3 study of postmenopausal women at risk of osteoporosis, 
bazedoxifene 10, 20, and 40 mg showed to prevent bone loss and reduce bone turnover and 
was associated with a favorable endometrial, ovarian, and breast safety profile. (Ronkin et 
al., 2005; Pinkerton et al., 2009; Miller et al., 2008; Archer et al., 2009) 
A phase III, multicenter, double-blind, randomized, placebo-controlled study was designed 
exclusively to evaluate the efficacy of bazedoxifene for the prevention of fractures (Silverman 
et al., 2008). The study comprised 7,492 healthy postmenopausal women with osteoporosis 
with or without prevalent vertebral fractures. Participants were randomized to 20 or 40 mg per 
day of bazedoxifene, 60 mg of raloxifene, or placebo plus 1200 mg of calcium and 400 IU of 
vitamin D. The primary endpoint was the incidence of new vertebral fractures after 36 months. 
Secondary outcomes included, clinical vertebral fractures, worsening of vertebral fractures, 
non-vertebral fractures, breast cancer incidence, and changes in height. Both bazedoxifene 20 
and 40 mg prevented the incidence of vertebral fractures with a similar efficacy as raloxifene 
when compared to placebo. The 3-year incidence of new vertebral fractures were 2.3%, 2.5%, 
2.3%, and 4.1% in the bazedoxifene 20 mg, bazedoxifene 40 mg, raloxifene 60 mg, and placebo 
groups, respectively, with a significant reduction in relative risk for new vertebral fracture of 
42%, 37%, and 42%, respectively, versus placebo. There was in general no effect on non-
vertebral fractures, with incidence rates of 5.7% and 5.6% for the bazedoxifene 20 and 40 mg 
groups, respectively, compared with 5.9% for the raloxifene treatment group and 6.3% for the 
placebo group. Though, in a post-hoc analysis of women with higher risk for fractures (low 
femoral neck T-score and multiple vertebral fractures, n=1,772) bazedoxifene 20 mg 
demonstrated a 50% and 44% reduction in non-vertebral fracture risk compared with placebo 
(HR=0.50; 95% CI: 0.28–0.90; p=0.02) or raloxifene 60 mg (HR=0.56; 95% CI: 0.31–1.01; p=0.05), 
respectively. (Silverman et al., 2008)  
2.5.3 Bazedoxifene and conjugated estrogen combination therapy 
The rationale for selecting bazedoxifene as the SERM in this combination is that it may 
counterbalance estrogen stimulation of endometrial and breast tissue, without the 
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requirement for using a progestin in women with an intact uterus or menopausal vasomotor 
symptoms, while preserving or increasing BMD. (Gruber & Gruber, 2004; Lewiecki, 2007a) 
The combination of a SERM with conjugated estrogen has directed to a new class of 
menopausal therapy called “tissue selective estrogen complex (TSEC)”. (Stovall & 
Pinkerton, 2008) 
Preclinical studies have shown that bazedoxifene antagonizes estrogen-induced uterine and 
mammary gland stimulation more effectively than other SERMs like raloxifene and 
lasofoxifene. (Peano et al., 2009; Kharode et al., 2008) A randomized, double-blind, placebo-
controlled Phase III trial in 3,397 postmenopausal women examined the effect of 
bazedoxifene 10, 20, or 40 mg combined with conjugated estrogens 0.625 mg or 0.45 mg on 
bone and endometrium. In this trial, the bazedoxifene plus conjugated estrogen combination 
therapy showed a statistically significant increase in BMD and a decrease in bone 
biochemical turnover markers compared with placebo. In addition to the positive effects on 
bone, bazedoxifene plus conjugated estrogen therapy significantly reduced the incidence 
and severity of hot flushes and improved vulvo-vaginal atrophy compared with placebo, 
with a good safety and tolerability profile. (Archer et al., 2009; Lobo et al., 2009; Pickar et al., 
2009; Lindsay, 2011) 
2.5.4 Safety 
Miller et al., showed that deep venous thromboembolism was rare with bazedoxifene (0% to 
0.6% with various doses after 2 years) and similar to placebo (0.3%). Leg cramps were 
similar to raloxifene and placebo. Hot flushes incidence and severity were comparable to 
raloxifene, but a little higher than with placebo. (Miller et al., 2008) In the study by 
Silverman et al, leg cramps (10.9% to 11.7% with various doses after 3 years) and deep 
venous thromboembolism (0.4% to 0.5% with various doses after 3 years) were significantly 
more common with bazedoxifene than with placebo (8.2 for leg cramps and 0.2% for deep 
venous thromboembolism), while breast cyst/fibrocystic breast disease was significantly 
less frequent. No difference between bazedoxifene and placebo were observed for 
myocardial infarction, strokes (ischemic or hemorraghic), or retinal vein thrombosis. (Miller 
et al., 2008; Silverman et al., 2008; Mitwally, 2008)  
In conclusion, bazedoxifene seems to have enhanced selectivity compared to other SERMs. 
Preclinical and clinical studies suggest slight stimulatory effects on uterine tissue and the 
ability to antagonize estrogen uterine effects. In addition, it does not appear to increase hot 
flushes. In vitro studies suggest inhibitory effects, at the breast although no long-term 
clinical data is available on effects on breast cancer rates. The effect of bazedoxifene on the 
skeleton is similar to raloxifene, and bazedoxifene may be used just as raloxifene. The value 
of bazedoxifene may reside in a different risk profile than raloxifene, especially in terms of 
uterine safety, and bazedoxifene may consequently offer an alternative for prevention and 
treatment of osteoporosis. 
2.6 Lasofoxifene 
Lasofoxifene is potent third generation SERM, discovered through a synthetic program 
intended to isolate innovative molecules with good oral bioavailability and higher potency 
in vivo. It is a naphthalene derivative, structurally different from the first- and second-
generation SERMs raloxifene, tamoxifen and clomiphene or idoxifene. Lasofoxifene has 
potent estrogenic and anti-estrogenic activity in vitro and in vivo, targeting any tissues that 
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have estrogens receptors, such as bone, uterus, breast, blood vessels, and liver. Competitive 
binding experiments demonstrate high affinity of the compound for both ERα and ER. Like 
other SERMs, lasofoxifene specifically binds to human ERα with high affinity and with a 
half-inhibitory concentration (IC50) which is similar to that seen with estradiol and 
consequently at least 10-fold higher than those reported for raloxifene, tamoxifen and 
droloxifene. Lasofoxifene also shows a high affinity for the human ER similar to the one of 
estradiol. (Gennari et al., 2010; Peterson et al., 2011; Swan et al., 2010) 
Lasofoxifene has been investigated in postmenopausal women for the prevention and 
treatment of osteoporosis as well as for the treatment of vaginal atrophy. In a 2-year, 
randomized, double-blind study comprising 410 postmenopausal women, the mean change in 
lumbar spine BMD compared to placebo was significantly greater (p<0.05) with lasofoxifene 
0.25 and 1.0 mg/day (3.6% and 3.9%, respectively) compared with raloxifene 60 mg (1.7%), 
although the results were comparable in total hip BMD. Lasofoxifene, as well as raloxifene, 
significantly reduced bone turnover markers and low-density lipoprotein cholesterol 
compared with placebo. Results have shown that treatment with lasofoxifene improves signs 
and symptoms of vaginal atrophy, as well as dyspareunia. (McClung et al., 2006a) 
Safety and tolerability of lasofoxifene is comparable to that of raloxifene, although 
discontinuation rates due to adverse events are more common with lasofoxifene. In spite of 
these findings, evidence proves that lasofoxifene treatment may cause increased 
endometrial thickness compared with placebo, even though there has been no evidence of 
an increased risk of endometrial hyperplasia or cancer. Lasofoxifene did not get FDA 
approval for the treatment of vaginal atrophy. (Kulak Junior et al., 2010) 
The PEARL trial, a 3-year pivotal fracture trial demonstrated that lasofoxifene increased 
lumbar spine and femoral neck BMD by roughly 3%. Moreover vertebral fractures were 
reduced by 42%, and non-vertebral fractures by 27%, with reduction in markers of bone 
turnover. Even though, lasofoxifene did not prevent hip fractures. (Clarke & Khosla 2009) 
2.7 Bisphosphonates 
2.7.1 Overview and mechanism of action 
Bisphosphonates belong to a class of antiresorptive drugs, whose antifracture action is well 
established in randomized controlled trials. It is important to remember that a direct 
comparison between them has not been made, which avoids establishing a clear superiority 
order. There were attempts to compare them through the respective trials and the respective 
risk reductions, but this approach has limitations that can only be overcome with direct and 
randomized trials of the different drugs. 
Bisphosphonates reduce the risk of fracture due to its inhibitory action of osteoclasts, which 
allows the osteoblasts to synthesize bone in the resorption spaces and some bone lacunae. 
This leads to an increase in bone mass. But, in addition, the bisphosphonates improve bone 
quality, by preserving the bone architecture, as shown in trials, in which the biopsies of the 
treated patients and controls have been studied. When the treatment with bisphosphonates 
is indicated, it is essential to administer calcium and vitamin D to assure its maximum 
antifracture efficacy. (Olmos-Martinez & Gonzalez-Macias 2008) 
Farnesyl pyrophosphate synthase (FPPS) is an essential regulatory enzyme in the 
mevalonate pathway. This pathway is important for the production of dimethylallyl 
pyrophosphate (DMAPP) and isopentenyl pyrophosphate (IPP), which serve as the 
foundation for the biosynthesis of molecules used in processes as diverse as terpenoid 
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synthesis, protein prenylation, cell membrane maintenance, hormones, protein anchoring, 
and N-glycosylation. It is also very important in steroid biosynthesis. Blocking this pathway 
has a variety of clinical uses, i.e. with statins for the inhibition of hydroxymethylglutaryl-
CoA reductase and thus reducing cholesterol biosynthesis, and nitrogenated 
bisphosphonates used for osteoporosis treatment. (Kavanagh et al., 2006) 
Bisphosphonates are pyrophosphate analogs in which the central oxygen has been 
substituted by a carbon atom and two side chains (R1 and R2). Their intestinal absorption is 
very low but the affinity for bone is extreme, and once there, they act as very potent 
antiresorptives. Two phosphate groups are essential so they can bind to bone and for the 
antiresorptive effect. The long side-chain (R2) determines the chemical properties, the mode 
of action and the strength of bisphosphonate drugs. The short side-chain (R1), principally 
influences pharmacokinetics and chemical properties. (Olmos-Martinez & Gonzalez-Macias 
2008; Kavanagh et al., 2006) 
While some of the first generation bisphosphonates such as etidronate and clodronate act by 
reversing pyrophosphorylytic reactions catalyzed by aminoacyl-tRNA synthetases, thus 
producing the corresponding pyrophosphonate analogs of adenosine tri phosphate and 
osteoclast apoptosis, the action of the nitrogenated bisphosphonates involves a different 
mechanism, inhibiting the FPPS activity in the mevalonate pathway. Their superior potency 
results from two main properties: the affinity for bone mineral and the ability to inhibit 
osteoclast function. (Olmos-Martinez & Gonzalez-Macias 2008)  
The difference in potency of the different nitrogenated bisphosphonates depends on their 
affinity for bone and their capacity of inhibiting FPPS. Their affinity for bone tissue provide 
bisphosphonates with the capacity of remaining embedded in bone matrix for a long time, 
thus providing the possibility of weekly, monthly or even yearly regimens. As mentioned 
earlier, bisphosphonates are poorly absorbed by the intestine (between 1% and 3%) and 
consequently bioavailability can vary considerably. The new third generation 
bisphosphonates are administered intravenously, avoiding this difficulty and accordingly 
increasing the effect of these drugs. (Olmos-Martinez & Gonzalez-Macias 2008) 
2.8 Etidronate 
This bisphosphonate was the first one introduced into osteoporosis treatment. At the 
present time, it is practically not used anymore. Its biggest advantage is probably its price. It 
increases bone mass in the spine and femur. It reduces the incidence of vertebral fractures; 
however it has not proven to diminish femoral fractures. Its administration is oral and 
cyclic, a dose of 400 mg, once a day, during 2 weeks and repeated every 90 days. During the 
intervals calcium is administrated. There is only one study where its intravenous 
administration was compared with clodronate and placebo for a short period, and it 
reduced bone mass loss in the spine. 
2.9 Clodronate 
It has been used for postmenopausal osteoporosis treatment in oral and intravenous 
regimes. The studies show that it prevents bone loss in vertebral spine when comparing 
with controls, and it has similar effects to estrogens at 2 years. In a 6-year trial, it was 
observed that it not only increased bone mass, but it also reduced vertebral fractures. 
McCloskey et al. conducted a 3-year, double blind, placebo controlled trial to study the 
effect of oral clodronate (800 mg daily) in fracture prevention. In this trial clodronate was 
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associated with a significant increase in the mean lumbar spine and hip BMD. Moreover, it 
significantly reduced vertebral fracture risk (relative risk, 0.54; 95% CI, 0.37-0.80; p<0.0001). 
Rovetta et al. have published a study that shows that treating osteoporotic vertebral 
fractures with 300 mg of intravenous clodronate may have better results than paracetamol in 
reducing pain. In spite of these results, since the discovery of the potent nitrogen 
bisphosphonates, the first generation bisphosphonates have been relegated to the last line of 
treatment. (McCloskey et al., 2004)  
2.10 Alendronate (Alendronic acid) 
Alendronate is one of the bisphosphonates most widely used. It increases vertebral bone 
mass around 6-8% and 3-6% at the hip in postmenopausal osteoporotic women treated for 3 
years. It shows a decrease of vertebral and non-vertebral fractures of about 50% in this 
period of time. Ninety five percent of postmenopausal women respond maintaining or 
increasing bone mass. Alendronate has shown to be able to prevent loss of bone mass of 
postmenopausal young women with osteopenia and in fragile old women living in 
retirement homes. In male osteoporosis, it has showed increases of 5% in bone mass at 2 
years of treatment. There is reliable security data of the drug at 10 years. Alendronate is 
approved by the Food and Drug Administration (FDA) of the United States for the 
treatment of osteoporosis in men and glucocorticoid-induced osteoporosis. 
It is administered orally, in weekly doses of 70 mg, fasting with 200 ml of water. The intake of 
food or drinks has to be avoided in the next 30 minutes and orthostatism has to be kept for this 
time. There is a preparation of alendronate, which has been available since 2007, that combines 
the drug with 2,800 U or 5,600 IU of vitamin D. Even though it is commercialized with another 
name, it is administered in the same way as alendronate alone and it is indicated in patients 
that need a supplement of vitamin D, but have an adequate intake of calcium.  
The pivotal trial of alendronate, the FIT (Fracture Intervention Trial), showed that the risk of 
any clinical fracture was lower in the alendronate than in the placebo group (139 (13.6%) vs 
183 (18.2%); relative hazard=0.72 (0.58-0.90)). The relative hazards for hip fracture and wrist 
fracture for alendronate versus placebo were 0.49 (0.23-0.99) and 0.52 (0.31-0.87). (Black et al. 
1996) Ensrud et al. published the analysis of a sub group of patients of the FIT. These patients 
were patients at high risk of fracture. Their results show a 47% significant reduction in risk of 
new vertebral fractures in the alendronate group compared with the placebo group. The 
reduction in risk of new vertebral fracture was consistent across fracture risk categories 
including age (RR=0.49 in women < 75 years compared with 0.62 in those ≥75 years), BMD 
(RR=0.54 in women with a femoral neck BMD < 0.59 g/cm2 [median] compared with 0.53 in 
those with a BMD ≥ 0.59 g/cm2), and number of preexisting vertebral fractures (RR=0.58 in 
women with 1 vertebral fracture compared with 0.52 in those with ≥ 2). The overall significant 
28% reduction in risk of incident clinical fractures in the alendronate group compared with the 
placebo group was also observed within these subgroups. (Ensrud et al., 1997)  Several other 
publications have derived from the FIT population, studying multiple symptomatic fractures, 
bone mineral density, biochemical markers of formation and resorption, fracture prevention in 
osteopenic women, effect of alendronate continuation versus discontinuation, and effect in 
those women who lost bone during treatment. (Levis et al., 2002; Bauer et al., 2004; Chapurlat 
et al., 2005; Quandt et al., 2005) 
In conclusion, alendronate is a well-tolerated, safe and effective drug for the treatment of 
postmenopausal osteoporosis, osteoporosis in men and glucocorticoid induced osteoporosis.  
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2.11 Risedronate 
This drug has showed to increase bone mass in spine and hip and to significantly reduce the 
risk of fracture in postmenopausal women. Treatment of postmenopausal women with 
osteoporosis with risedronate during three years has shown to reduce vertebral fractures in 
approximately 50% and non-vertebral fractures in 39%. At the hip, the fracture reduction is 
between 40 and 60%. At 5 years, the results are similar. The drug has shown anti fracture 
efficacy after 6 months of administration. In other studies it has been confirmed that the 
efficacy still remains after 7 years of treatment with a good security profile. Risedronate has 
shown to be efficient in the prevention of spinal and femoral bone mass loss in patients with 
osteopenia. The first available preparation was 5 mg that was administered daily. A couple 
of years later a preparation of 35 mg became available and had to be taken weekly. Finally, 
about two years ago, a preparation of 150 mg came out to be taken every month. In Europe, 
this preparation was split into two 75 mg capsules that have to be taken on consecutive days 
once a month. Every dosage preparation of risedronate has to be taken following the 
instructions of oral bisphosphonate administration mentioned earlier.  
In one of the main trials of risedronate, McClung et al, studied 5445 women 70 to 79 years 
old diagnosed with osteoporosis (T score at the femoral neck more than -4 SD below the 
mean or lower than -3 plus a non-skeletal risk factor for hip fracture, such as poor gait or a 
tendency to fall) and 3886 women at least 80 years old with at least one non-skeletal risk 
factor for hip fracture or low bone mineral density at the femoral neck (T score, lower than -
4 or lower than -3 plus a hip-axis length of 11.1 cm or greater). The patients were randomly 
assigned to receive treatment with oral risedronate (2.5 or 5.0 mg daily) or placebo for three 
years. The primary end point was the incidence of hip fracture. The results showed that the 
incidence of hip fracture among the patients assigned to risedronate was 2.8%, as compared 
with 3.9% among those assigned to placebo (relative risk, 0.7; 95% CI, 0.6 to 0.9; p=0.02). In 
the group of women with osteoporosis (those 70 to 79 years old), the incidence of hip 
fracture among those assigned to risedronate was 1.9%, as compared with 3.2% among those 
assigned to placebo (relative risk, 0.6; 95% CI, 0.4 to 0.9; p=0.009). In the group of women 
selected primarily on the basis of non-skeletal risk factors (those at least 80 years of age), the 
incidence of hip fracture was 4.2% among those assigned to risedronate and 5.1% among 
those assigned to placebo (p=0.35). (McClung et al., 2001) 
To evaluate vertebral fracture risk reduction, Reginster et al, completed a randomized, 
double-blind, placebo-controlled study to determine the efficacy and safety of risedronate in 
the prevention of vertebral fractures in postmenopausal women with established 
osteoporosis. The study was conducted at 80 study centers in Europe and Australia. A total 
of 1226 postmenopausal women with two or more prevalent vertebral fractures received 
risedronate 2.5 mg or 5 mg daily or placebo. The study lasted 3 years; however, the 2.5 mg 
group was discontinued by protocol amendment after 2 years. Lateral spinal radiographs 
were taken annually for evaluation of vertebral fractures, and BMD was measured every 6 
months. Risedronate 5 mg reduced the risk of new vertebral fractures by 49% over 3 years 
compared with control (p<0.001). A significant reduction of 61% was observed within the 
first year (p = 0.001). The fracture reduction was similar in both groups at 2 years. The non-
vertebral fracture risk was reduced by 33% compared with control over 3 years (p = 0.06). 
Risedronate significantly increased BMD at the spine and hip within 6 months. In 
conclusion, risedronate 5 mg was an effective and well-tolerated therapy for severe 
postmenopausal osteoporosis, reducing the incidence of vertebral fractures and improving 
bone density in women with established disease. (Reginster et al., 2000)  
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2.12 Ibandronate 
Its absorption is similar to the one of the rest of the oral bisphosphonates since only 0,6% of 
the administrated dose is absorbed. The administration instructions are also the same as the 
other oral bisphosphonates, because if it is administered concomitantly with food, the 
plasmatic concentrations can decrease up to 90%. In studies at 3 years, it has shown to 
reduce vertebral fractures (52%) and increase vertebral BMD (6.5%) without presenting 
significant adverse effects or changes in bone histology. It also avoids bone loss in 
postmenopausal women with osteopenia and it has proven to be very efficient in preventing 
bone loss in Glucocorticoid-induced osteoporosis. In women with severe osteoporosis (T 
score <-3), it reduces non-vertebral fractures up to 69%. (Chesnut, 2006) 
It is administered orally in a monthly dose of 150 mg and also intravenously every three 
months in a dose of 2 mg. Randomized clinical trials like MOPS (Monthly Oral Pilot Study) 
or MOBILE (Monthly Oral Ibandronate in Ladies) have shown that the ibandronate monthly 
dose is as effective and secure as the daily dose. In the general population of the pivotal trial 
(BONE, Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and 
Europe), the frequency of adverse events of the gastrointestinal tract in the daily dose and 
the intermittent dose was comparable to the one of placebo. Dyspepsia was the only adverse 
event with a slight superior frequency in patients in active treatment with ibandronate. 
(Delmas et al., 2004) 
In different chronic therapeutical areas it has been shown that, for oral bisphosphonates, the 
treatment compliance is poor and, besides, it decreases with time. This has a big impact on 
the drug’s effectiveness, since the early interruption and bad compliance decrease 
significantly the benefit that these drugs could have. In order to show the importance of the 
problem, a sub study, with data of the IMPACT study was made. More than 2,300 
postmenopausal women were treated for osteoporosis with risedronate. The analysis 
showed, that, in contrast to the women who did not accomplish the treatment, most of the 
women, who complied with the treatment, had decreases in the bone resorption markers. In 
other analysis, that included patients with osteoporosis and osteopenia from a Canadian 
data base, it was shown that patients with a treatment compliance higher than above 80% 
had increases in bone mineral density and these were significantly higher than the ones 
from patients who did not accomplish this requirement. The strict administration 
requirements that are needed caused some patients to interrupt the treatment with 
bisphosphonates and it was a reason for some not to start it. In a 6-month study with 
alendronate, 14.3% of the patients mentioned discomfort as the reason for interrupting the 
treatment. In prospective trials of crossover treatment it has been shown that the least 
frequent administration of bisphosphonates increases the treatment compliance. That is why 
the use of ibandronate with monthly intake could be of benefit. (Delmas et al., 2007) On the 
other hand, ibandronate has not shown, in randomized controlled trials, reductions in the 
incidence of non-vertebral or hip fractures. 
2.13 Zoledronate (Zoledronic acid) 
Zoledronic acid is a third generation bisphosphonate. Its complete chemical name is 1-
hydroxi-2-(1H-imidazol-1-y-1)ethylidene) bisphosphonic acid. The experience with this 
drug is more extensive in the oncology area. Besides oncology, zoledronic acid has other 
non-oncological indications like postmenopausal osteoporosis treatment, established 
osteoporosis treatment, glucocorticoid induced osteoporosis, male osteoporosis and Paget’s 
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disease of the bone. The difference is not only in the indication, since the administration 
regime is also different.  
Zoledronate is approximately 2-3 times more potent than pamidronate, it is more or less as 
potent as alendronate, risedronate and ibandronate, but when it is administrated 
intravenously, the gastrointestinal adverse effects are avoided and the bioavailability 
increases, while at the same time, it increases the compliance to 100%. The pharmacokinetics 
of the drug is very similar to that of the other bisphosphonates. The highest plasmatic 
concentration is reached just after the infusion, with a posterior descent of approximately 
10% in 4 h, followed by 1% in the next 24h. The mean urine excretion of the drug is around 
44% of the administered dose, which means that the bone tissue absorbs more than 50% 
from the administered zoledronate. 
The HORIZON study (Health Outcomes and Reduced Incidence with Zoledonic Acid Once 
Yearly Pivotal Fracture Trial) is a multicentric, international, double blind, placebo-
controlled trial of postmenopausal women with osteoporosis, whose objective was to show 
superiority of 5mg of intravenous zoledronic acid against placebo administrated during a 
period, not shorter than 15 min. In this study, as in most osteoporosis studies, patients received 
1.000-1.500 mg of calcium and 400-1.200 U of vitamin D. The patients had densitometric 
osteoporosis or densitometric osteopenia with at least 2 mild to moderate vertebral fractures. 
(Lyles et al., 2007) Finally, more than 7.700 patients took part in the study and were followed 
for 3 years; paying special attention to new fractures, bone remodeling biochemical markers 
and densitometric changes. At the end of the study, the patients that had received zoledronic 
acid showed a reduction in the vertebral fracture risk of 70%. The reduction was similar for the 
first and second year of the study, ranging from 60 to 71%. Besides, patients treated with 
zoledronate showed a reduction of 41% in hip fracture risk and 25% in non-vertebral fracture 
risk. The results of bone density and biochemical bone remodeling markers were also 
significantly better for the group of patients treated with zoledronic acid. Moreover, the 
increase in bone mineral density was over 6% in the lumbar spine and total hip, and over 5% 
in the femoral neck. The biochemical markers of bone remodeling, after the first infusion of 
zoledronic acid, experienced an important decrease, as expected, and they remained stable 
during the whole study. (Black et al., 2007) 
Many patients showed adverse effects during the study, being more frequent in the 
treatment group. The difference was basically the post-infusion syndrome. This syndrome 
appeared usually 24-48 hours after the zoledronic acid infusion, just as described by other 
intravenous bisfosfonates, it happens sometimes, even with the ones administrated orally, 
and it disappears on the third day post-infusion. The symptoms are light fever, myalgias, 
flu-like syndrome, headache and/or arthralgias and they disappear with analgesic, non-
steroid anti-inflammatory drugs or paracetamol. The episode appears usually after the first 
infusion and in seldom cases, after the second one. It shows an incidence with a clear 
descendent pattern in the later infusions. Some of the patients showed transient renal 
function deterioration from 9 to 11 days after the infusion, however it did not have any 
clinical transcendence. (Black et al., 2007) 
Probably the most important finding related to the treatment with zoledronate would be the 
28% decrease in mortality independent of the cause, showed in a population of over 2.000 
patients with femur fracture. (Lyles et al., 2007) 
In conclusion, zoledronate treatment is very efficient for the decrease of vertebral, non-
vertebral and hip fractures. It decreases mortality for any cause after a femur fracture. 
www.intechopen.com
 
Pharmacological Treatment of Osteoporosis 571 
Besides, it is a secure treatment that eludes the gastrointestinal adverse events and the bad 
adherence that are usually seen with other bisfosfonates, but it has to be remembered that, 
due to its administration route, zoledronate is not for ambulatory use and it has to be 
administrated very carefully in patients with chronic renal impairment, and those who need 
to get dental extractions. 
2.14 Cost effectiveness 
Economical evaluation in medicine includes different types of studies that enable us to give 
the population better care and attention with resources that are limited. Among the many 
different types of analysis, we can find cost reduction assays, analysis of cost-effectiveness 
(mostly used), analysis cost-utility and cost-benefit. The cost-effectiveness analysis is 
probably the easiest to evaluate, since it expresses the monetary units needed to change the 
units normally used in clinical practice (viral charge, number of fractures avoided or quality 
adjusted life years, QALY). (Sacristan et al., 2004a, Sacristan et al., 2004b) 
Internationally a sanitary intervention is considered to be cost-effective if the additional cost 
for QALY gained, in comparison with another intervention, is below the 50.000.00 US$ and 
it is not when it is higher than 100.000.00 US$. In Spain, the amount used is € 30.000.00 in 
order to validate the acceptance of interventions. However, there are many authors, who 
consider this value to be excessively low. (Sacristan et al., 2004a, Sacristan et al., 2004b) 
In a review of cost-effectiveness analysis, in which 23 studies were included, and some of 
which included more than 90 clinical trials, it was demonstrated that the available 
bisfosfonates in Spain show that the cost of risedronate, compared with no treatment in 
women with previous fracture is of € 43.601.00 and for alendronate € 49,483.00. In women 
without previous fracture the values increase to € 61,604.00 for risedronate and € 88,634.00 
for alendronate, both compared with patients not treated. If we consider only patients over 
65 years old, treatment with alendronate as well as with risedronate result cost-effective in 
patients with previous fracture as well as in patients with no previous fracture. As expected, 
the bigger the population is, the more cost effective is treatment with bisphosphonates. (Van 
Staa et al., 2007; Fleurence et al., 2007) 
It is important to consider that this data is subject to several conditions, such as the 
comparator and the sample used during the clinical trials, but most importantly the price of 
the drug. The data used in the Spanish studies presented previously are from 1999, which 
differ from the actual reality. There are other studies that analyze new bisfosfonates as 
ibandronate and zoledronate, but not for osteoporosis. 
2.15 Security of bisphosphonates 
These drugs are usually well tolerated, as long as they are taken in a scrupulous way and 
the intake instructions are followed. Esophageal ulcerations have been known to occur 
when the drugs are administrated orally and daily. In spite of the good profile that its 
weekly administration has, it should not be administered to individuals with gastric 
ulceration or esophageal ulceration, or to those who present pyrosis (heartburn) and require 
medication. They should not be administrated to pregnant women, or to patients with 
severe renal function impairment. The intravenous bisphosphonates usually produce acute 
phase reactions with fever, arthromyalgia and flu like syndrome, that usually disappear by 
the second administration and that can be relieved with the concomitant use of paracetamol 
or ibuprofen. Hypocalcaemia can appear more often; therefore it is wise to use calcium and 
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vitamin D concomitantly. The renal function has to be controlled before and after the 
administration of intravenous bisphosphonates. 
Avascular necrosis of the jaw, also called osteonecrosis of the jaw is an illness that has 
worried many physicians, ever since Marx described it for the first time in 2003 and it will 
be described in detail in another chapter. (Marx, 2003) 
2.16 Long-term effects of the treatment with bisphosphonates: Atypical hip fractures 
Reports associating atypical fractures of the femur with long-term use of bisphosphonates 
led the initiative of the American Society for Bone and Mineral Research (ASBMR) to form a 
task force to address key questions related to this finding. The task force defined major and 
minor features of incomplete and complete atypical femoral fractures and recommended 
that all major features, including their location in the subtrochanteric region and femoral 
shaft, transverse or short oblique orientation, minimal or no associated trauma, a medial 
spike when the fracture is complete, and absence of comminution, be present to appoint a 
femoral fracture as atypical. Minor features include their relationship with cortical 
thickening, a periosteal reaction of the lateral cortex, prodromal pain, bilaterality, delayed 
healing, co-morbid conditions, and concomitant drug use, including bisphosphonates, other 
antiresorptive agents, glucocorticoids, and proton pump inhibitors. Preclinical data 
evaluating the effects of bisphosphonates on collagen cross-linking and maturation, 
accumulation of micro-damage and advanced glycation end products, mineralization, 
remodeling, vascularity, and angiogenesis provide biologic plausibility to a potential 
association with long-term use of bisphosphonates. Based on published and unpublished 
data and the extensive use of bisphosphonates, the incidence of atypical femoral fractures 
associated with bisphosphonate use for osteoporosis appears to be very low, particularly 
compared with the number of vertebral, hip, and other fractures that are prevented. 
Furthermore, a causal association between bisphosphonates and atypical fractures has not 
been established. However, recent observations imply that the risk rises with increasing 
treatment duration, and there is concern that lack of knowledge and underreporting may 
mask the real incidence of the problem. Given the relative infrequency of atypical femoral 
fractures, the task force recommends that specific diagnostic and procedural codes be 
created and that an international registry be established to assist studies of the clinical risk 
factors and optimal surgical and medical management of these fractures. Physicians should 
be made aware of the possibility of atypical femoral fractures through a change in labeling 
of bisphosphonates. (Shane et al., 2010) 
A study comprising 12,777 Swedish women 55 years of age or older, who sustained a 
fracture of the femur in 2008 was published recently. Radiographs of 1,234 of the 1,271 
women with a subtrochanteric or shaft fracture were reviewed. Fifty-nine patients with 
atypical fractures were identified. The relative and absolute risk of atypical fractures 
associated with bisphosphonate use was estimated by means of a nationwide cohort 
analysis. The 59 case patients were also compared with 263 control patients who had typical 
subtrochanteric or shaft fractures. The cohort analysis showed an age-adjusted relative risk 
of atypical fracture of 47.3. The increase in absolute risk was 5 cases per 10,000 patient-years. 
A total of 78% of the fractured patients and 10% of the controls had received 
bisphosphonates (multivariable-adjusted odds ratio of 33.3). The risk was independent of 
coexisting conditions. After drug withdrawal, the risk diminished by 70% per year since the 
last use (odds ratio, 0.28; 95% CI, 0.21 to 0.38). (Schilcher et al., 2011) 
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2.17 Biological agents 
The illnesses that provoke bone loss, like osteoporosis, derive from the imbalance in the 
cycles of bone remodeling favoring bone resorption. The receptor activator of the nuclear 
factor kB (RANK), a member of the tumor necrosis factor (TNF) family proteins, and its 
ligand (RANKL) are fundamental for differentiation, activation and survival of osteoclasts 
and, therefore, basic mediators of the regulation of bone remodeling. (Anderson et al., 1997; 
Burgess et al., 1999; Lacey et al., 1998) It has been demonstrated that the signaling of the 
RANKL is involved in the pathophysiology of many bone loss illnesses, such as primary 
and many secondary osteoporoses. RANKL production is increased when estrogen is 
decreased. (Eghbali-Fatourechi et al., 2003) This condition occurs in menopause and in 
circumstances of hormonal ablation, and leads to an increase in bone resorption. In animal 
studies with knockout mice lacking RANKL, an absence of osteoclast can be seen, and 
consequently an increase in bone density. (Kong et al., 1999)  
2.18 Denosumab 
Denosumab, a fully human monoclonal IgG2 antibody to RANKL imitates the effects of 
osteoprotegerine (OPG), endogenous inhibitor of RANKL blocking bone resorption. 
Denosumab presents a much longer half-life and it is highly specific since it does not bind to 
other members of the TNF family, including TNF, TNF-related apoptosis-inducing ligand, 
or CD40 ligand. (Bone et al., 2008; Kearns et al., 2008; Kostenuik et al., 2009) The binding of 
denosumab to RANKL prevents rank activation and inhibits the formation, activation and 
survival of osteoclasts.  
Comercial denosumab comes as a sterile, colorless solution intended for subcutaneous 
injection. It comes ready for administration in a 60mg/ml syringe-vial. The prefilled syringe 
drug product contains denosumab at 60 mg/mL, 17 mM sodium acetate, 4.7% sorbitol, and 
0.01% polysorbate 20, at a pH of 5.2, filled to a target deliverable volume of 1.0 mL.  
2.18.1 Pharmacodynamics and pharmacokinetics 
The pharmacodynamic profile of denosumab appeared alike across all the subject 
populations studied. So far it has been studied in healthy postmenopausal women 
(including a Japanese population), healthy men ≥ 50 years of age, subjects with advanced 
cancer and bone metastases (breast cancer, other solid tumors [excluding lung], and 
multiple myeloma), and subjects with rheumatoid arthritis. The results indicate that SC 
administration of 60 mg denosumab causes a quick reduction in bone resorption within 6 
hours, assessed by the marker C-telopeptide of type 1 collagen (CTX1) in serum 
(approximately 70% reduction), with an approximately 85% reduction occurring by 3 days.  
Serum CTX1 reductions were maintained for 6 months after the 60-mg dose, with the serum 
CTX1 reductions partially attenuated from a maximal reduction of ≥ 87% to reductions of 
approximately 45% or greater (range 45% to 80%), reflecting the reversibility of its effects on 
bone remodeling. The pharmacokinetics following IV or SC administration of denosumab 
has been studied at doses up to 3 mg/kg or 210 mg in various populations, including all 
those described earlier. Following subcutaneous administration, denosumab exhibits dose 
dependent, nonlinear pharmacokinetics over a wide dose range (as observed for other 
monoclonal antibodies). Nevertheless, dose-proportional increases in exposure were 
observed for doses ≥ 60 mg, consistent with saturable and non-saturable mechanisms of 
elimination. Its bioavailability is approximately 60% after SC injection. No accumulation in 
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serum denosumab concentrations was observed with repeated doses of 60 mg every 6 
months. There is no evidence that the rare (approximately 0.5% of treated subjects) and 
transient development of binding antibodies to denosumab influences its pharmacokinetics 
or pharmacodynamics. Changes in serum calcium levels following administration of 
denosumab are not related to the extent of exposure. (Yonemori et al., 2008; Perez-Edo, 2011) 
2.18.2 Denosumab in human clinical trials 
Information is available from 44 clinical trials in healthy adults and patients with 
osteoporosis (approximately 13,500 subjects), bone loss associated with hormone-ablation 
therapy (approximately 1,900 subjects), rheumatoid arthritis (approximately 200 subjects), 
advanced cancer (multiple myeloma and advanced malignancies involving bone 
[approximately 7,800 subjects]) and giant cell tumor of the bone (approximately 260 
subjects) collected between June 2001 to November 2010. 
In the Denosumab Fortifies Bone Density (DEFEND) trial, a phase III randomized, placebo 
controlled study, of 332 postmenopausal women with osteopenia and stratified according to 
the beginning of menopause (<5 years, >5 years), denosumab demonstrated a significant 
increase in lumbar BMD (6.5%) at 24 months, compared with placebo (-0.6%). It also 
increased BMD in other locations as total hip, distal third of the radius, and whole body (p> 
0.001) in the two patients' strata. The incidence of adverse effects was similar between the 
placebo group and the denosumab group. (Bone et al., 2008) 
In a comparative clinical trial, the DECIDE (Determining Efficacy: Comparison of Initiating 
Denosumab vs. Alendronate) trial, comprising 1,189 postmenopausal women with low BMD 
(T-score: ≤-2 SD), patients were randomized 1:1 to receive subcutaneous denosumab (60 mg 
every 6 months) plus oral alendronate placebo weekly or oral alendronate weekly (70 mg) 
plus a subcutaneous denosumab placebo injection every 6 months. Denosumab increased 
total hip BMD when compared to alendronate (3.5 % vs. 2.5 %, p <0.00001). A greater 
increase in BMD could be seen with denosumab than with alendronate in other locations, as 
in the trochanter (4.5 % vs. 3.5 %), distal radius (1.1 % vs. 0.6 %), lumbar spine (5.3 % vs. 4.2 
%) and femoral neck (2.2 % vs. 1.6 %); p <0.0003. The safety profile was similar for the two 
groups. No patient included in the study developed antibodies against denosumab. (Brown 
et al., 2009) 
Another phase III, multicenter, double blind study, called STAND (Study of transitioning from 
Alendronate to Denosumab) was performed to evaluate the effect of denosumab in patients 
who were receiving alendronate. Five hundred four postmenopausal women ≥ 55 years of 
age with a BMD T-score of <-2.0 and >-4 SD, who were receiving weekly oral alendronate 
for at least 6 months, were randomized and treated for 44±33 months. Changes in BMD and 
bone biochemical markers were evaluated. At 12 months the group receiving denosumab 
(but previously treated with alendronate) showed a significantly higher increase in total hip 
BMD compared to those still receiving alendronate (1.9% vs. 1.05%; p<0.00012). Significantly 
higher BMD increases with denosumab compared with alendronate were also seen at 12 
months at the lumbar spine, femoral neck, and distal radius (all p<0.0125). The adverse 
events and serious adverse events were similar in both groups of treatment. (Kendler et al., 
2010) 
Finally, the main phase III trial, the FREEDOM (Fracture Reduction Evaluation of Denosumab in 
Osteoporosis every 6 Months) trial, comprised 7,868 postmenopausal women with 
osteoporosis with a BMD T-score between <-2.0 and >-4 SD and evaluated the efficacy in 
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fracture reduction of denosumab. The patients received 60 mg subcutaneous denosumab or 
placebo every 6 months for 36 months. Around 23% of the patients had a previous vertebral 
fracture. The patients' retention rate in the study was 83%. The new fracture relative risk 
reduction was 68% (2.3% vs. 7.2%; p<0.0001) for vertebral fractures, 20% (6.5% vs. 8.0%) for 
non-vertebral fractures and 40% (0.7% vs. 1.2%) for hip fractures. As compared with subjects 
in the placebo group, subjects in the denosumab group had a relative increase of 9.2% in 
bone mineral density at the lumbar spine and 6.0% at the total hip at 36 months. There were 
no significant differences between subjects who received denosumab and those who 
received placebo in the total incidence of adverse events, serious adverse events, or 
discontinuation of study treatment because of adverse events. No cases of osteonecrosis of 
the jaw were observed in either group. (Cummings et al. 2009) 
In conclusion, denosumab offers a highly effective alternative to the treatment of 
osteoporosis by decreasing bone resorption and increasing bone mineral density through 
the inhibition of RANKL.  
2.18.3 Cost effectiveness studies of the treatment with denosumab 
One of the clear advantages of denosumab is its administration route and dosage. A 
subcutaneous injection every 6 months is very comfortable and increases the adherence to 
treatment. This finding is very important when establishing the cost-effectiveness 
advantages of any treatment since fracture prevention is improved when adherence is 
optimal. In order to establish the cost-effectiveness of denosumab compared to generic 
alendronate, branded risedronate, strontium ranelate and no treatment in a Swedish setting, 
Jönsson et al, designed a Markov cohort model and followed them for 5 years. The mean age 
of the Typical Swedish patient population is 71 years old, with a mean BMD T-score of ≤ 2.5 
SD and a prevalence of morphometric vertebral fractures of 34%. Treatment persistence and 
residual effect after discontinuation was assumed to be equal to the time on treatment. 
Persistence with the comparators and with denosumab was derived from prescription data 
and a persistence study, respectively. The base-case incremental cost-effectiveness ratios were 
anticipated at €27,000, €12,000, €5,000, and €14,000, for denosumab compared with generic 
alendronate, risedronate, strontium ranelate, and no treatment, respectively. Fracture and unit 
costs, as well as mortality rates for the general population were based on data from 2008. 
Suboptimal persistence had the greatest impact in the comparison with generic alendronate, 
where the difference in drug cost was larger. They concluded that persistence improvement 
impacts positively on cost-effectiveness increasing the number of fractures prevented in the 
population targeted for osteoporosis treatment. (Jonsson et al., 2011) In another similar study, 
denosumab was cost effective compared with all other therapies. In particular, denosumab 
was found to be cost effective compared with branded alendronate and risedronate at a 
threshold value of €30,000 per QALY and denosumab was dominant (lower cost and greater 
effectiveness) compared with risedronate from the age of 70 years in women with a T-score of -
2.5 or less and no prior fractures. (Hiligsmann & Reginster, 2011)  
3. Anabolic agents 
3.1 Fluoride 
Fluoride is the anion F-, a monovalent ion (-1 charge). At high doses it can be lethal to 
humans. At low doses, 1 to 2 mg per day, it prevents dental caries. At intermediate doses, 
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ranging from 8 to 80 mg daily, skeletal fluorosis can develop. These doses are not so rare, 
they can be found in some regions with high fluoride levels in well waters or in some 
industrial settings. It was thought to be a therapeutical agent after observing the 
osteosclerosis effect at high doses. (Heaney, 1994) 
Many years ago, endemic fluorosis was described in patients living in regions with high 
fluoride water levels or grounds where vegetables and tea were cultivated, like some places 
in India. Moreover some observations were published describing a low fracture incidence in 
patients living in areas with high fluoride levels. It was used for the treatment of 
osteoporosis for the first time in 1961. It was approved for the use of osteoporosis 
prevention in several countries in Europe, but it never got the approval from the American 
Federal Drug Administration (FDA). (Pandey & Pandey 2011; Turner, 1996) 
3.1.1 Pharmacokinetics 
Two different types of compounds have been used for the treatment of osteoporosis: sodium 
fluoride and monofluorophosphate. Sodium fluoride could be found as capsules or tablets 
with an enteric protection. A more recent preparation is the sustained release formulation. 
The ion equivalences usually used were: monofluorophosphate 200 mg containing 16,4 mg 
of fluoride and sodium fluoride 50 mg containing 22,6 mg if the ion. (Watts, 1999) 
Absorption and bioavailability of fluoride preparations depend on their formulation. Thus 
sodium fluoride is quickly absorbed in the stomach with maximum plasma fluoride levels 
30 minutes after ingestion with almost a 100% bioavailability, while sodium 
monofluorophosphate absorption is slower with a bioavailability around 65%. It is cleared 
by the kidney and about 50% of absorbed fluoride is deposited in the skeleton. Its 
distribution is not homogeneous since higher amounts are deposited in areas with high 
bone remodeling rate, such as trabecular bone. (Ekstrand & Spak, 1990) 
3.1.2 Mechanism of action 
Fluoride increases bone formation increasing osteoblasts proliferation, without altering their 
differentiation. The molecular basis of this mitogenic action is not known, but there are 
several hypotheses. The most popular one indicates that fluoride induces an increase in 
tyrosine phosphorilation of signaling proteins of the mitogenic process. Besides this effect 
over the osteoblastic cells, fluoride modifies the crystallization of the bone tissue. Thus 
replacing hydroxylic radicals of hydroxyapatite, forming fluoroapatite, a compound with a 
lesser structural stability and more resistance to osteoclastic resorption. (Marie et al., 1992) 
3.1.3 Effect of fluoride in bone mineral density and fracture risk reduction 
Results from studies evaluating the effect of fluoride compounds on BMD agree that this 
agent increases lumbar spine BMD in a consistent and linear manner. The increases in spinal 
BMD vary between 2.3 and 9% annually. A recent meta-analysis establishes the mean 
increase of spinal BMD in 8.1% at two years and 16.1% at four years, when comparing it to 
placebo. The increase in BMD depends on the doses, formulation and fluoride compound 
used. An interesting finding among all the trials is that there are 25% of patients considered 
as non-responders, since they did not experience any change in BMD during the fluoride 
treatment. (Heaney, 1994; Haguenauer et al., 2000a) 
The results of the trials that have studied the effect of fluoride in fracture risk reduction are 
inconclusive. Some studies have demonstrated the decrease in the incidence of vertebral 
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fractures with monofluorophosphate, (Reginster et al., 1998) or sodium fluoride 
treatment,(Farrerons et al., 1997) while other studies, using the same preparations and 
doses, failed in doing so. Vestergaard et al, in 2008 published a meta-analysis including 25 
different studies and concluding that in spite of the BMD increase in spine and femur, 
fluoride treatment did not reduce significantly vertebral risk of fracture. (Vestergaard et al., 
2008) Moreover, another meta-analysis goes even further and establishes the increase in 
fracture risk with increasing doses at four years. (Haguenauer et al., 2000a; Haguenauer et 
al., 2000b)  
3.1.4 Toxicity 
The adverse events seen with fluoride treatment are varied. The most frequent ones are 
gastrointestinal symptoms and acute lower extremities pain. The frequency and intensity of 
these effects is dose and preparation dependant. Gastrointestinal symptoms include 
dyspepsia, epigastralgia, nausea and vomiting, and they appear in 10% to 40% of patients. 
Lower extremity pain is quite common also, appearing in around 15% of patients, especially 
in those patients receiving high doses of sodium fluoride or monofluorophosphate. Some 
authors have established a relationship between these pains and development of stress 
fractures. (O'Duffy et al., 1986) 
Finally, bone biopsies have demonstrated that patients treated with fluoride develop an 
abnormal bone, consistent with an increase of trabecular width, volume and trabecular 
surface covered with osteoid material which can be seen inside mineralized bone. When 
analyzing dynamic histomorphometric indices, a reduction in tetracycline labeling and an 
extension in the mineralization interval can be seen. Both findings indicate a mineralization 
defect. (Lundy et al., 1995) 
3.2 Parathyroid hormone and analogs 
Among the many therapeutic options teriparatide or recombinant human PTH (1-34), 
occupies an important place. It is classified into a group of anabolic bone-forming drugs as 
opposed to the anti-resorptive or catabolic. Teriparatide is given as daily subcutaneous self-
administered injections.  
It induces de novo bone formation by increasing the rate of bone turnover in favor of 
formation. The treatment with teriparatide increases trabecular connectivity and cortical 
bone thickness. (Dempster et al., 2001) Teriparatide improves bone mechanical properties 
resulting in a significant decrease in vertebral and non-vertebral fractures in 
postmenopausal women with osteoporosis, male osteoporosis and corticosteroid-induced 
osteoporosis. (Keaveny et al., 2007) That is why its use is considered appropriate mainly in 
patients at high risk of fracture and in those who have failed previous treatments. 
(Hodsman et al., 2005) 
The fundamental physiological action of parathyroid hormone (PTH) is the maintenance of 
calcium homeostasis to maintain nearly constant concentrations through the tubular 
resorption of calcium by stimulating calcium absorption in the bowel by vitamin D, 
increasing renal 1- hydroxylase. 
The effect exerted by PTH on the skeleton is complex. High levels of PTH observed in 
primary and secondary hyperparathyroidism, leading to increased bone resorption by its 
action on osteoclasts, produce secondary osteoporosis. In contrast, low levels increase the 
osteoblastic activity of bone formation. This would contrast with the desired effect by 
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administering PTH as a treatment for osteoporosis. However, it was observed that the action 
of the hormone on bone varies if administration is continuous (emulating persistently high 
levels of hyperparathyroidism) that induce catabolic effects on bone, or intermittent (as 
given in treatment) which also increases resorption as well as formation of bone. 
3.3 Teriparatide (1-34 parathohormone) 
The first available indication for teriparatide was the treatment of established osteoporosis 
in postmenopausal women. Of the various existing studies on this drug, the FPT (Fracture 
Prevention Trial) is the most important. It compared teriparatide at doses of 20 or 40 g/day 
versus placebo in 1637 postmenopausal women with vertebral fractures. Patients receiving 
teriparatide achieved significant reductions in the rate of new vertebral and non-vertebral 
fractures. They also produced an increase in lumbar and femoral neck bone density. 
Although 40 g/day achieved greater effects on BMD, fracture risk was not significantly 
different between the two doses, while the higher dose was less tolerated (11% of 
withdrawals due to adverse effects with 40 g/day versus 6% with 20 g/day or placebo). 
The dose of 20 g/day showed a reduction in vertebral fracture risk of 65% and a non-hip 
non-vertebral fracture risk reduction of 35%. This study was initially planned to last for 36 
months, but it was stopped when patients had completed an average of 21 months for 
security measures due to osteosarcomas observed in drug toxicity studies in rats. (Neer et 
al., 2001) However, in other studies it became clear that this finding occurred only in young 
rats treated with high doses of PTH. (Vahle et al., 2004) Moreover, no cases have been 
reported in humans.  
A subgroup of patients were followed for up to 18 months after cessation of treatment. The 
subgroup of women who had received teriparatide showed a persistent 40% reduction in 
vertebral fracture risk at 18 months compared with placebo. These results suggest that the 
benefit on the incidence of non-vertebral fractures persist once it has been stopped. (Lindsay 
et al. 2004) 
3.3.1 Combination therapy: Teriparatide plus antiresorptives 
Although currently bisphosphonates are the gold standard in the treatment of osteoporosis, 
there are several trials that have evaluated if the association of teriparatide and BP has any 
beneficial effect. The studies suggest that if both drugs are administered simultaneously, 
bisphosphonates do not enhance, but on the contrary, seem to blunt the anabolic effect of 
teriparatide.  
Finkelstein et al. also carried out a study in men with three groups, receiving PTH (1-34), 
alendronate or the combination of both. In this last group, PTH (1-34) was started at month 
six. All three groups were followed for 30 months. Spine BMD as measured by DXA and 
quantitative computed tomography. BMD was increased to a greater extent in the PTH 
group than in the alendronate or the combination group. Thus, these studies show no 
evidence of synergy between PTH and alendronate. Furthermore, alendronate may impair 
the anabolic activity of PTH. It is hypothesized that PTH is less effective when bone 
turnover is suppressed. (Finkelstein et al. 2003) 
3.3.2 Teriparatide in patients previously treated with antiresorptives 
Once the antagonistic effect of antiresorptives and teriparatide was observed a study was 
conducted to evaluate the response of teriparatide in patients previously treated with 
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antiresorptives. The EUROFORS study was a prospective, open-label, randomized trial of 
865 postmenopausal women with established osteoporosis and was designed to investigate 
various sequential treatments of teriparatide over 24 months. Patients were classified into 
various groups depending on their previous treatments. The results of the BMD changes 
and biochemical markers of bone formation showed that treatment with teriparatide 
induces positive effects on bone mass and osteoblast function regardless of previous long-
term exposure to antiresorptive therapies in postmenopausal women with established 
osteoporosis.  
Duration of antiresorptive therapy and elapsed time between stopping previous therapy 
and starting teriparatide did not affect the BMD response at any skeletal site. The skeletal 
responses at the lumbar spine were similar among previous antiresorptive therapy groups 
at each time point during the study, although previous users of etidronate showed a higher 
increase, probably reflecting its weaker anti-remodeling activity. At month 6, total hip and 
femoral neck BMD significantly decreased in the previous alendronate subgroup, and total 
hip BMD significantly decreased in the previous risedronate subgroup. Total hip and 
femoral neck BMD was numerically decreased from baseline in all other subgroups at 6 
months. However, this transient decrease was reversed with longer teriparatide treatment. 
All subgroups showed a statistically significant increase in BMD compared with baseline 
after 18 and 24 months of treatment, and without differences between the groups at any 
time point in the study. (Obermayer-Pietsch et al., 2008) 
3.3.3 Sequential therapy 
In another non-randomized study, 59 postmenopausal women with osteoporosis previously 
treated with raloxifene or alendronate for 18-36 months, were given 18-month treatment 
with teriparatide. Changes in BMD and bone-turnover markers were assessed. Women who 
had previously been treated with alendronate had a late increase in bone-turnover markers 
with values lower than one third those of patients who had previously received raloxifene. 
During the first 6 months there were significant differences in the increase in BMD at the 
lumbar spine and hip. Women previously treated with raloxifene had a greater increase in 
BMD at the two locations. At 18 months of treatment in the lumbar spine significant 
differences remained in favor of prior treatment with raloxifene, but in the hip differences 
were not significant. This demonstrates that treatment with teriparatide increases bone 
turnover in patients previously treated with raloxifene or alendronate, but this increase is 
greater and earlier in raloxifene pretreatment group. (Ettinger et al., 2004) 
3.3.4 Corticosteroid-induced osteoporosis and male osteoporosis 
There are also trials showing efficacy of teriparatide in the treatment of glucocorticoid-
induced osteoporosis. In a randomized, double blind trial, 428 patients of both sexes aged 
between 22 and 89 years who had received corticosteroids for at least 3 months were 
randomized to receive alendronate 10mg/day or 20 g/day of teriparatide for 18 months. 
After 12 months the total femur BMD was higher in the teriparatide group and at the end of 
study there were less vertebral fractures in the teriparatide group. (Saag et al., 2009) 
Teriparatide has also been used in men with osteoporosis. The study compared men with 
idiopathic or secondary osteoporosis receiving teriparatide vs. placebo. The study showed 
increases independently of gonadal status and other factors in the teriparatide group. 
(Orwoll et al., 2003) 
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3.3.5 Side effects 
In general, teriparatide, recombinant human PTH (1-34), injections are well tolerated. It is 
cleared from the circulation within four hours of subcutaneous administration. A daily 
injection is necessary and transient redness at the injection site has been noted. Headache 
and nausea occur in less than 10% of subjects receiving a daily dose of 20 µg Mild, early, and 
transient hypercalcemia can occur, but severe hypercalcemia is rare. Increases in urinary 
calcium (by 30 µg per day) and serum uric acid concentrations (by 13%) are seen but do not 
appear to have clinical consequences.  
In conclusion, teriparatide is a suitable and efficient treatment option for osteoporosis. It is 
effective in several clinical problems, such as male osteoporosis or corticosteroids induced 
osteoporosis.  
3.4 1-84 Parathormone 
Intact PTH (PTH 1-84) has been described as having a positive effect on bone micro 
architecture and a reduction in the risk of new fractures due to a bone-forming mechanism. 
(Rosen & Bilezikian, 2001) 
1-84 PTH (as well as 1-34 PTH) acts through its receptor, exerts its action in bone through 
osteoblasts by modulating the levels of cAMP by activating secondary messengers it acts on 
the osteoclast bone resorptive process. In collagen tissue, PTH in high and sustained doses 
inhibits its synthesis, but at low doses and used intermittently, through the action of IGF-1, 
it stimulates its synthesis.  
PTH also increases the local synthesis of IGF-1, which may explain its anabolic effect in bone 
tissue. Other actions of PTH include modulation of TGF B1 and the production of 
prostaglandins that may contribute to bone formation, acting on the pre-osteoblast 
differentiation stage. And it is through the IGF-1 that it inhibits apoptosis.  
This mechanism distinguishes the effect of treatment with PTH of other treatments that 
inhibit the resorption stage of bone remodeling acting on osteoclast (like bisphosphonates). 
The ability of PTH to act directly on the osteoblast, the cell that directly produces new bone, 
drives in the enhancement of production of new bone with consequent gain in bone mineral 
density and fracture risk reduction.  
3.4.1 Clinical use of 1-84 PTH 
Hodsman et al. conducted a study in 217 postmenopausal women with osteoporosis, with a 
mean age of 64.5 years, who were randomly classified into different groups receiving 
placebo or PTH 1-84 at doses of 50, 75, or 100 mcg. The primary endpoint was change in 
BMD at the lumbar spine after 1 year of treatment. The results showed a mean increase in 
BMD of 3.0%, 5.1% and 7.8% in the group receiving 50, 75 and 100mcg/day of 1-84 PTH 
respectively, compared with placebo, with all increases clearly statistically significant, 
whereas in the control group receiving calcium and vitamin D, there was an increase of 0.9% 
that did not reach statistical significance. The increase in BMD obtained by the group that 
received 100 mcg was statistically significant with respect to the other two groups receiving 
PTH, passing from a T-score of -3.2 at baseline to -2.8 at the end of treatment. In contrast 
there were no statistically significant differences in BMD at the hip. (Hodsman et al., 2003) 
The pivotal clinical trial with 1-84 PTH is the TOP (Treatment of Osteoporosis) study. It 
comprised 2,532 postmenopausal women with osteoporosis receiving PTH (1-84) or placebo. 
The follow up was up to 18 months.  The main goal was the reduction in vertebral fracture 
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risk. Mean age of patients in the study was 64 years, and of them, 19% had at least one 
vertebral fracture. After 18 months, the increase in BMD at the lumbar spine in women 
treated with PTH (1-84) was 7% compared with the placebo group. The risk of new vertebral 
fractures decreased by 66% in the group treated with PTH. Hypercalcemia was observed in 
28.3% of treated women, compared to 4.7% in the control group. (Greenspan et al., 2007) 
3.4.2 Combination and sequential therapy 
The effects of concurrent or sequential therapy with PTH and antiresorptive agents have been 
studied. Black et al. compared the effects of PTH (1-84), alendronate, or both in combination in 
postmenopausal women in the study PaTH. In this study, 238 postmenopausal women were 
randomized with ages comprised 55-85 years with a T-score <-2.5 or a T-score <- 2 and with at 
least one risk factor or additional fracture. Initially there were 3 groups receiving:  PTH (1-84) 
100 mcg/day + placebo (n=119), alendronate (ALN) 10mg/day + placebo (n=60) and PTH  
(1-84) 100 mcg/day + ALN 10 mg / day (n=59). All participants received daily calcium 500mg  
+ vitamin D (400UI) supplements. (Black et al., 2003) 
At one year, spine DXA had increased in all three groups. There was no difference in spine 
DXA between the PTH group and the combination group. However, the PTH group had a 
significantly greater increase in volumetric BMD of the spine on quantitative CT than the 
alendronate and combination groups. Volumetric trabecular lumbar BMD increased with 
respect to baseline by 26%, 13% and 11% in the PTH alone, PTH and alendronate and 
alendronate group respectively at 12 months. Similarly, volumetric trabecular BMD of the 
total hip increased by 9%, 6% and 2% respectively in the 3 groups.  
3.4.3 Effects on bone architecture 
In spite of the facts of all these studies previously published, data about what was 
happening in bone was lacking. Recker et al. studied bone biopsies from iliac crest from 
postmenopausal osteoporotic women who received placebo (n=8) or 100 mcg PTH(1-84) for 
18 (n=8) or 24 (n=7) months to assess cancellous and cortical bone formation and structure. 
Using micro CT and histomorphometry at 18 months, cancellous bone volume (BV/TV) 
measured was 45-48% higher in subjects treated with PTH(1-84) versus placebo, and also 
resulted in a higher trabecular number (Tb.N) and thickness. The higher Tb.N appeared to 
result from intra-trabecular tunneling. Connectivity density was higher and structure model 
index was lower, indicating a better connected and more plate-like trabecular architecture. 
Cancellous bone formation rate (BFR) was 2-fold higher in PTH (1-84)-treated subjects, 
primarily because of greater mineralizing surface. (Recker et al.,2009) 
3.4.4 Adverse effects 
The physical effects produced by PTH 1-84 are in most cases mild. The most common is 
hypercalcemia, present in 28% of women treated vs. 4.6% in the placebo group and 
hypercalciuria, 46% versus 23% respectively. However, the number of withdrawals of 
treatment due to this cause was rare in published clinical trials (two patients in the PaTH 
study and six patients in the TOP study) and generally the effect was controlled by 
removing the supplements of calcium and vitamin D. Although it is believed that 
hypercalcemia could slightly modify electrocardiographic studies decreasing the QT 
interval without significant changes or minimal changes in heart rate, PR interval or QRS 
duration and axis, no differences between groups were observed. Other reported side 
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effects, although often not as important as the ones mentioned above, were nausea and 
vomiting. Fisher et al, reported a study with 344 rats treated with nearly life-long daily 
teriparatide, and found an increased risk of osteosarcoma. Nevertheless, to date there is no 
reported increase in prevalence of osteosarcoma in humans treated with neither teriparatide 
nor PTH 1-84, and no association has been found between primary hyperparathyroidism 
and osteosarcoma. Recently, Tashjian et al. reported that they had not collected a single case 
of osteosarcoma in humans, following the prescription of more than 250,000 treatments with 
PTH, 1-34 and 1-84 after follow-up of patients who participated in the studies with PTH 1-84 
in the 80’s. (Tashjian & Goltzman, 2008) 
4. Dual action agents 
4.1 Strontium ranelate 
Strontium (Sr) is a chemical element with an atomic number 38. It is an alkaline earth metal 
and was isolated for the first time, as an impure substance, in 1808 in a Scottish city named 
“Strontain” from which this element received its name. It is in this city where strontium is 
found in higher concentrations than usual (73g/kg). The earth cortex contains 0.042% of 
strontium and is as abundant as chloride and sulfur. It can also be found in rocks, dust, 
carbon and oil, as well as in some foods as cereals, green vegetables and milk. In marine 
water, strontium is the most abundant trace element, reaching values of 8 mg/L. (Cabrera et 
al., 1999) In its natural state, called stable strontium, this element is not radioactive and it is 
harmless. The only compound harmful for the human being is strontium chromate, and due 
to chrome not to strontium. (Levy et al., 1986) The therapeutic potential of strontium was 
discovered around 1940, when strontium-89 was used as an analgesic agent in bone 
metastases from prostate cancer. (Giammarile et al., 1999; Saarto et al., 2002) Afterwards this 
isotope, together with strontium-88, have been used as markers for calcium absorption. 
(Cabrera et al., 1999)  
4.1.1 Pharmacological characteristics 
The main entrance of strontium into the body is through the gastrointestinal system. The 
skin and the lungs can also absorb it. Its gastrointestinal absorption varies with age and has 
a very high variability in infants. In the elderly, the fluctuation is about 10%. A number of 
absorption mechanisms have been proposed, beginning with the passive mechanisms and 
diffusion, to transporter mediated absorption, as proposed by Papworth et al. Strontium 
absorption augments with fasting and it is seriously affected by calcium, phosphorus and 
other chelating agents in the bowel and its absorption rate is about half of calcium. Other 
experimental studies have demonstrated that during pregnancy and breast-feeding 
strontium absorption is increased, reaching a maximum during breast-feeding. (Papworth & 
Patrick 1970; Papworth & Vennart, 1984) 
Absorption of strontium is dose dependant. Its bioavailability decreases with a lower dose, 
confirming that, just like calcium, absorption involves passive diffusion, independent of 
vitamin D levels, as well as saturable active transport, regulated by vitamin D and a 
facilitated diffusion. (Ardissino et al., 2000) Studies in a variety of animals (i.e. rats or 
monkeys) demonstrate that the pharmacokinetic data of renelic acid have a high variability. 
It is estimated that its oral absorption is poor and slow, probably due to a deficient intestinal 
permeability. (Li et al., 2006) 
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Serum concentration of strontium can be affected by the administration together with 
calcium and with meals. When administered together with 0,5 grams of calcium, strontium 
relative bioavailability decreased 57%, 63% when administered with meals and 71% when 
administered with calcium and meals. Due to these absorption difficulties, several studies 
were conducted in order to determine the best mode of administration. Comparing 
strontium administration one hour before breakfast and three hours after breakfast to every 
12 hours resulted in a decrease of bioavailability of 46 and 55% respectively. In phase 2 
studies no difference was observed between giving strontium 1 gram every 12 hours or 2 
grams before bedtime. Thus, to guarantee the best absorption and bioavailability, it is 
recommended to administer strontium ranelate two hours after dinner. (Leeuwenkamp et 
al., 1990; Reginster & Meunier 2003) Vitamin D seems to increase the medications’ 
absorption, though in phase 3 studies it was observed that the influence of vitamin D did 
not change strontium availability in more than 10%, which is clinically insignificant. 
(Ardissino et al., 2000; Leeuwenkamp et al., 1990; Marie, 2003) 
Strontium excretion is mainly through renal clearance, and to a lesser extent through feces 
and sweat. In healthy adults, strontium plasma clearance varies between 9.4 and 11.7 
ml/min, meanwhile the urinary clearance is between 4.0 and 5.4 ml/min. (Papworth & 
Vennart, 1984; Leeuwenkamp et al., 1989) In animal studies, the bone tissue strontium 
content decreased to approximately 50% at week 6 to 10 after stopping treatment. Renelic 
acid, given its high polarity, is poorly absorbed and its half-life in animals is about 1 hour, 
though it varies according to its absorption. In humans, renelic acid excretion is 
approximately 78 ml/min and therefore it has a half-life of 2.6 hours. (Li et al., 2006; 
Leeuwenkamp et al., 1990) 
Due to its chemical properties, strontium can form complexes with oral tetracyclines and 
quinolones, and therefore its administration with these medications is not recommended. 
Strontium administration together with diuretics could increase its serum concentration 
around 20%. This effect is greater with thiazide diuretics, furosemide and indapamide, and 
could be explained by the increase in the strontium tubular re-absorption, together with 
calcium, which would rise in parallel. Even though this increase in strontium levels is not 
clinically significant and no dose adjustment is needed. Magnesium and aluminum 
hydroxide can significantly decrease strontium bioavailability, therefore it is not 
recommended to take these medications at night, when strontium should be administered. 
(Leeuwenkamp et al., 1990; Marie, 2003) 
4.1.2 Mechanism of action 
In-vitro, strontium ranelate increases collagen and non-collagen protein synthesis thru 
mature osteoblasts. The bone forming effects were confirmed with the increase in the 
replication of pre-osteoblastic cells. This stimulus of the replication of the pre-osteoblastic 
cells and the increase of collagen and non-collagen proteins are the reason why strontium 
ranelate is considered as a dual effect bone agent, since it does not only decrease resorption. 
(Bonnelye et al., 2008) In an in-vitro assay of isolated rat osteoclasts, the pre-incubation of 
bone slices pre-treated with strontium ranelate, demonstrated a dose dependant decrease in 
bone resorption activity. In another assay, using chicken bone marrow, a dose dependant 
decrease in the expression of carbonic anhydrase II and the alpha subunit of the vitronectin 
receptor could be observed. (Takahashi et al., 2003; Caverzasio, 2008; Bonnelye et al., 2008; 
Reginster et al., 2003) 
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The main mechanism of action that rules bone resorption at a molecular level is the 
RANK/RNAKL/OPG system described earlier. Concentrations of 0.1 mM to 2 nM of 
strontium ranelate, decrease the ability of human osteoblasts of inducing osteoclast 
differentiation, by decreasing expression of mRNA of RANK-L and increasing mRNA 
expression of OPG, according to the studies done by Brennan et al in 2006. (Close et al., 
2006; Chapurlat & Delmas,  2004) 
The human body has a very strict extracellular calcium control mechanism. This control is 
performed by varied body tissues with the aim of keeping extracellular calcium levels 
within a narrow range, which is essential for the normal cellular function including 
muscular contraction, nerve impulse transmission or platelet aggregation, for example. 
The tissues involved in this task, like the chief cells of parathyroid glands, C cells of the 
thyroid glands, renal tubules, the cortical ascending limb of the nephron, the intestinal 
epithelium and the bone cells like osteoclasts and osteoblasts, express a receptor capable 
of detecting changes in the extracellular calcium levels and act according to the 
requirements, these receptors are called calcium receptors or calcium sensing receptors 
(CaR). (Brown 2003) 
Several studies with cell cultures have been able to demonstrate that this receptor can be 
activated by other divalent cations, including strontium, which just as calcium but with a 
lower potency can activate the CaR. This means that in the presence of strontium, chief cells 
of the parathyroid glands will decrease its secretion and that osteoclasts will decrease bone 
resorption, for example. Numerous assays demonstrate that 0.13 nM strontium plasma 
levels, like the ones seen in patients treated with 2 g of strontium ranelate daily, won’t affect 
the CaR in soft tissues. The effect on osteoclast apoptosis could be related to the activation of 
the transmembrane receptor attached to phopholipase C (CaR) and mediated by an 
independent signaling pathway of IP3-protein kinase C. Some other authors suggest that 
besides CaR, there are other receptors that can also influence these actions. These receptors 
could be related to the stimulating effect of strontium on osteoblasts replication in CaR 
knockout rats. (Arlot et al., 2008; Brown, 2003) 
4.1.3 Effects on other tissues 
Some studies have demonstrated that strontium ranelate has beneficial effects in tissues 
other than bone. Taking cartilage for example, strontium ranelate increased basal 
production of proteoglycans stimulated by insulin growth factor 1 by chondrocytes of 
young subjects, old subjects and subjects with osteoarthritis. On the contrary, it showed no 
effect on the proteoglycans production induced by interleukin 1 (IL-1), the stromelycin 
production stimulated by IL-1 or chondrocytes activity. These findings suggest that 
strontium ranelate stimulates human cartilage matrix formation in vitro without activating 
the chondroresorption process. (Henrotin et al., 2001) 
4.1.4 Effect of strontium ranelate in fracture reduction 
It is known that due to the chemical properties of the compound (a higher molecular 
weight), densitometric values of patients treated with strontium ranelate will be higher than 
the true values. There are many studies that have measured the influence of the chemical 
characteristics of strontium on densitometry and have developed some mathematical 
formulas to remove this influence from the DMO value. These formulas are a little bit 
complicated and require too much time to put them into practice in the daily practice, 
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therefore the utility of these formulas is restricted to almost only research. It is easier and 
almost accurate to calculate that half of the DMO gained in the first year of treatment with 
strontium ranelate is due to an increase on BMD and the rest is due to the higher molecular 
weight on strontium measured by the DXA. (Blake & Fogelman, 2006b) 
Currently we have data from clinical studies comparing strontium ranelate to placebo for 
fracture prevention for up to five years. Moreover we have data of fracture incidence in 
patients treated with strontium ranelate for up to 10 years. The phase III pivotal trial was 
performed in 75 centers distributed through 12 countries worldwide. It was structured in 
three different clinical trials. The FIRST (Fracture International run-in for Strontium 
Ranelate) trial mean duration was 101 days (SD  52) and was performed with the objective 
of normalizing calcium and vitamin D levels of all subjects. From this trial the other two 
were derived, the SOTI (Spinal Osteoporosis Therapeutic Intervention) trial and the 
TROPOS (Treatment of Peripheral Osteoporosis) trial. (Reginster & Meunier, 2003; Reginster 
et al., 2005) The main propose of these trials was to evaluate the effect of strontium ranelate 
in axial and appendicular skeleton as well as the tolerability in postmenopausal osteoporotic 
women. Their main objective was to calculate the reduction in the incidence of new 
vertebral fractures (SOTI trial) as well as non-vertebral fractures (TROPOS trial). (Reginster 
et al., 2008) The analysis included 1649 postmenopausal women in the SOTI trial and 5091 
patients in the TROPOS trial. In the SOTI trial women were randomized into two groups, a 
placebo (control) group and another one receiving 2 g daily of strontium ranelate for a 
period of four years. In the fifth year, the patients taking placebo switched to strontium 
ranelate and 50% of the ones taking strontium ranelate switched to placebo. In the TROPOS 
trial, all patients remained in their original treatment group during the whole 5 years. The 
preliminary three-year results showed a vertebral fracture reduction of 41% with a NNT of 
9. Furthermore an increase in BMD of 12.7% was observed. The vertebral fracture reduction 
at the end of the forth and fifth year was of 33% and 24%, respectively. Similar results were 
obtained from the TROPOS trial where the vertebral reduction rate was 39% at the end of 
the third year and 24% at the end of the fifth year. Regarding the non-vertebral fractures the 
decrease in the relative risk of fracture with strontium ranelate was 16% at the end of the 
third year and 15% at the end of the fifth. A post-hoc analysis of these data in a subgroup of 
1,977 patients with high fracture risk (74 years old and a T-score of -2.4) showed a 
vertebral fracture risk reduction of 36% at the end of the third year and 43% at the end of the 
fifth. (Blake & Fogelman, 2005; Reginster et al., 2007; Moro-Alvarez & Diaz-Curiel, 2007) 
Since there is no data showing the fracture reduction risk of strontium ranelate in placebo 
controlled patients, Reginster et al, compared the fracture incidence between the original 
strontium ranelate group at the end of the fifth year to the strontium ranelate group 
followed for ten years. The results are shown in table 2. (Reginster et al., 2010) These results 
show no statistically significant differences between the incidence of fractures at the end of 
year 5 or 10. An important fact to bear in mind is that the sample was significantly reduced 
since at the end of the tenth year, just 233 patients continued in the follow up study.  
Another sub study performed by Seeman et al, with patients over 80 years of age showed a 
reduction in the vertebral fracture risk of 32% in the third year and 31% in the fifth year. For 
peripheral fractures, the reduction in fracture risk was of 31% in the third year and 27% in 
the fifth year, and for hip fractures the risk reduction was 32% in the third year and 24% in 
the fifth. (Seeman et al., 2010; Seeman et al., 2006) 
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5 years with 
placebo 
5 years with 
Strontium ranelate 
10 years with 
strontium ranelate 
Vertebral fracture incidence 24.9% 18.5% 20.6 
Non-vertebral fracture 
incidence 
20.9% 12.9% 13.7% 
Table 2. Fracture incidence at 10 years. (Reginster et al., 2010) 
4.1.5 Adverse events 
At the end of the third year, in the phase III studies, the only adverse event that showed 
statistically significant differences compared to placebo was diarrhea, found in 6% of the 
patients taking the drug and 3.6% of the placebo group. Other adverse events found to be 
more frequent with strontium ranelate, but with no statistically significant difference 
compared to placebo, were nausea, headache, dermatitis, eczema, and thrombo-embolic 
events. The latter was studied thoroughly, but no relation to the drug was found. Other 
studies with high doses of strontium ranelate have been performed in order to investigate 
thrombo-embolism, but no alteration in coagulation parameters have been found to support 
the finding in the phase III trial. (Blake & Fogelman, 2006a; Halil et al., 2007; Liu et al., 2009; 
Ulger et al., 2010) 
At the end of the fifth year some other events were found to be more frequent (with no 
statistically significant differences compared to placebo) such as memory loss, cognitive 
impairment and seizures. The rest of the adverse events had the same incidence in the study 
drug and the placebo group. (Blake & Fogelman, 2006a; Liu et al., 2009)   
Strontium ranelate has been used widely in Europe and there is a rare adverse event 
reported to be due to treatment with this compound. Reports state that 0% to 8% of patients 
suffer a drug rash with eosinophilia and systemic symptoms (DRESS), which is an allergic 
reaction to the medication that usually appears between 3 and 6 weeks after starting 
treatment. This syndrome can be fatal if the medication is not stopped and treatment with 
glucocorticoids started. (Musette et al., 2010) 
5. Future therapies 
5.1 Cathepsine K (CatK) inhibitors 
Human cathepsin K is a 329 amino acid long protein consisting of an N-terminal 15 amino 
acid long signal sequence, a 99 amino acid long propeptide, and a 215 amino acid long 
catalytic unit. It shares about 60% protein sequence identity with cathepsins L, S, V and less 
than 35% with cathepsins F, O, B, H, and W. Cathepsin K is expressed predominantly in 
osteoclasts and various other multinucleated cells such as giant foreign body cells and 
Langhans cells. To a lesser degree it is found in macrophages, synovial fibroblasts, and 
fibroblasts at locations of wound healing or inflammation, chondrocytes, various epithelial 
cells of the human fetus, adult lung airway epithelium, thyroid epithelium, and possibly at 
low concentrations in smooth muscle cells. Once the enzyme is synthesized, it is sequestered 
into lysosomes and can be secreted into the extracellular environment. It is specifically 
secreted into the resorption lacuna underneath actively resorbing osteclasts where it is 
responsible for the degradation of the collagen type I dominated organic bone matrix. Thus, 
similarly to pycnoidisostosis, elimination of cathepsin K in osteoclasts results in inhibition of 
bone resorption. Inhibitors of cathepsin K are suggested to have less of an effect on 
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osteoclast–osteoblast interaction, resulting in less inhibition of bone formation, than 
available bisphosphonate antiresorptive agents. Human cathepsin K inhibitors have been 
shown to prevent bone loss in ovariectomized mice without blunting the anabolic action of 
parathyroid hormone (PTH). 
Although no CatK inhibitor is currently marketed for osteoporosis treatment or prevention, 
studies of three CatK inhibitors for the treatment of osteoporosis have been reported: 
balicatib, relacatib, and odanacatib.  
The most commonly used drugs for the treatment of osteoporosis inhibit osteoclast-
mediated bone resorption. Osteoclasts are hematopoietically derived multinucleated giant 
cells that resorb bone by focal attachment and demineralization, followed by the enzymatic 
degradation of organic bone matrix. The demineralization is achieved by the secretion of 
acid onto the bone surface. The organic matrix (mainly type 1 collagen, the principal bone 
matrix protein) is degraded primarily by the enzymatic action of cysteine proteases, 
particularly cathepsin K (CatK). CatK is the most abundantly expressed cysteine protease in 
osteoclasts and exhibits collagenolytic activity under acidic conditions. Currently treatment 
of osteoporosis, like bisphosphonates prevent acid secretion by disruption of the ruffled 
border and proton pump required for hydrogen ion secretion.  
The collagenases of the matrix metalloproteinase family have been considered as the main 
proteases for the degradation of collagen as they were thought to be the main ones capable 
of cleaving triple helical collagen. However, matrix metalloproteinase are active at neutral to 
slightly alkaline pH values whereas at the site of bone resorption, within the resorption 
lacuna, acidic pH conditions prevail. Thus, acidic lysosomal hydrolases were proposed to 
operate as the main collagen degrading proteases. Previously, only Cathepsins B and L were 
known. Cathepsins B and L were thought to be the key factors, as both enzymes were 
known to cleave in the telopeptide region of triple helical collagens. However in the early 
1990’s a new cathepsine was identified thanks to DNA clonation techniques. Initially this 
new cathepsine was identified only in osteoclasts and was called cathepsine O, later its 
name changed to cathepsine K. This protease exhibited a potent collagenase activity towards 
the main connective tissue collagens type I and II, and immunohistochemical analyses 
revealed a predominant but not exclusive expression in osteoclasts. After that, 
pycnodysostosis, a hereditary form of osteopretosis was related to a low level of Cathepsine 
K due to a complete deficiency. 
5.1.1 Balicatib 
Balicatib is highly selective for CatK in enzyme assays but has lesser selectivity in living 
cells. In vitro studies have shown that a basic moiety in its chemical structure results in its 
accumulation in the acidic environment of the lysosomes at concentrations sufficient to 
inhibit cathepsins B and L and possibly others. Clinical studies of balicatib have 
demonstrated BMD increases in postmenopausal women, but treatment was associated with 
cutaneous adverse events. The first demonstration of the effect of cathepsin K inhibitors on 
bone density in humans was seen with balicatib. This trial, published by Adami et al., in an 
ASBMR meeting in 2009 (Denver, CO, USA) was a multicenter, randomized, placebo-
controlled, 12-month, dose-range finding study of 675 postmenopausal women with lumbar 
spine T-score less than 2.0. In the group that received 50mg of balicatib daily, markers of 
bone resorption declined by more than 55% with no decline in markers of bone formation 
(osteocalcin, bone-specific alkaline phosphatase and N-terminal propeptide of type I 
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collagen). The BMD in the lumbar spine increased 4.46% and 2.25% in the total hip. Skin 
reactions, including pruritus and morphea-like changes, were noted in a small number of 
patients. In a small Japanese trial, intact PTH levels were shown to increase by 50% with 
balicatib treatment.  
5.1.2 Relacatib 
Relacatib is a potent but nonselective inhibitor of cathepsins K, L, V, and S for which no 
clinical information has been published. Administration of relacatib to ovariectomized and 
control monkeys resulted in an acute and rapid reduction of bone markers, and this effect 
lasted for up to 2 days depending on the dose delivered.  
Due to side effects, especially skin reactions, drug development of all cathepsin K inhibitors 
has been suspended or slowed down except for odanacatib and currently ONO 5334. 
5.1.3 Odanacatib 
Odanacatib is a powerful, reversible nonpeptidic biaryl inhibitor of cathepsin K that 
inactivates the proteolytic activity of cathepsin k. It is synthesized by replacing the P2-P3 
amide bond of an aminoacetronintrile dipeptide 1 with a phenyl ring. This results in a 
powerful, selective inhibitor with the capacity to inhibit cathepsin K in osteoclasts. (Bromme 
& Lecaille, 2009) 
Two studies have been carried out to evaluate the efficacy and safety of odanacatib, a phase 
I study to determine the dose and a phase II study to evaluate the safety and efficacy. In the 
Phase I study a group of 49 women was used to evaluate a weekly dose. Doses of 5mg, 25 
mg, 50mg, and 100 mg were used and 12 women were assigned to the placebo group. A 
group of 30 women was used to evaluate the daily dose. Doses of 0.5, 2.5, and 10mg were 
used, with 6 women assigned to the placebo group. All doses were administered in fasting 
conditions. Odanacatib had a long half-life of between 66 and 93 hours for all the regimes 
and doses used. The efficacy of weekly, and daily doses in modifying the markers was 
evaluated. The effect was dose-dependant although not dose proportional. Reductions in 
resorption markers were greatest for doses >50 mg weekly and doses ≥2.5mg daily. 
Maximum suppression was achieved between day 3 and day 5 with the weekly dose and 
was maintained until the following dose. (Stoch et al., 2009) 
The Phase II trial published by Cusick et al in the ASBMR meeting in 2009 (Denver, Co, 
USA), was a double-blind, randomized, placebo-controlled trial of 12 months duration with 
an anticipated extension period of 24 months. It included 399 post-menopausal women 
(postmenopausal (5yr) or bilateral oophorectomy) between 45 and 85 years,with a T-score <-
2 but not less than -3.5 at any site. Patients were divided into five groups according to the 
dose: placebo, 3 mg/weekly, 10 mg/weekly, 25mg/weekly and 50 mg/weekly. The changes 
in BMD at the lumbar spine were assessed and considered a primary objective. Also changes 
in bone remodeling, changes in BMD in other sites and adverse effects were evaluated. The 
results showed a dose-dependant increase in BMD in all sites. The greatest increase was 
obtained with the highest dose. Weekly administration of 50mg of odanacatib increased 
bone mass by 5.7% in the lumbar spine, 4.1% in the total hip, 4.7% in the femoral neck, 5.2% 
in the trochanter and 2.9% in the distal third of the radius at 24 months. Resorption markers 
fell in a dose-dependant manner from the beginning of treatment and remained reduced 
during the first six months, after which they increased and the differences with placebo 
disappeared. 
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The results of the extension of the phase II study to 36 months (published by Eisman et al at 
the ASBMR meeting 2009 in Denver, included 169 women who were randomized to 
odanacatib 50 mg and placebo weekly. In the odanacatib group, BMD continued to increase 
(lumbar spine 7.5%, total hip 5.5%, femoral neck 5.5% and trochanter 7.4%). The urine NTX 
resorption marker was 50% lower compared with placebo, whereas there were no 
differences in the BSAP (bone specific alkaline phosphatase) formation marker. At three 
years, formation markers were not only not reduced, but in fact increased by 18% over 
baseline values. 
5.1.4 ONO 5334 
ONO-5334 is a new cathepsin K inhibitor. There has been a first study to investigate the 
efficacy and safety of ONO-5334 in postmenopausal osteoporosis. This was a 12-month, 
randomized, double blind, placebo and active-controlled parallel-group study conducted in 
13 centers in 6 European countries. Investigators included 285 postmenopausal women aged 
55 to 75 years with osteoporosis. Subjects were randomized into one of five treatment 
groups: placebo; 50 mg twice daily, 100 mg once daily, or 300 mg once daily of ONO-5334; 
or alendronate 70mg once weekly. After a year of follow up all ONO-5334 doses and 
alendronate showed a significant increase in BMD at the lumbar spine, total hip (except 100 
mg once daily), and femoral neck. There was little or no suppression of ONO-5334 on bone-
formation markers compared with alendronate, although the suppressive effects on bone-
resorption markers were similar. There were no clinically relevant safety concerns. With a 
significant increase in BMD, ONO-5334 also demonstrated a new mode of action as a 
potential agent for treating osteoporosis. This new drug increases the armamentarium not 
only in cathepsin K inhibitors (the second that seems to be available) but also in osteoporosis 
treatment. (Eastell et al., 2011) 
In conclusion, Cathepsine K inhibitors are a new family of drugs that increase the 
armamentarium in the fight against fractures, as the most dangerous effect of osteoporosis. 
Having the possibility to treat this disease in different points of the resorption pathway is 
positive and it gives us the possibility to reach a better and easier way to decrease the 
incidence of fractures.  
5.2 Anti-sclerostin monoclonal antibody 
Sclerostosis is a rare autosomal-recessive disorder. Patients with this disease characterize for 
having a high bone mass. (Hamersma et al., 2003; Beighton, 1988; Barnard et al., 1980) The 
study of its etiopatogenesis led to the discovery of sclerostin, a protein that in humans is 
encoded by the SOST gene. (Balemans et al. 2001; Brunkow et al., 2001) It is classified as a 
key inhibitor of osteoblast-mediated bone formation. (Poole et al., 2005; Wergedal et al., 
2003) Loss-of-function mutations in this gene are associated with sclerosteosis, which causes 
progressive bone overgrowth and increases in bone mass and BMD.  
Another similar disease is van Buchem disease, which is a milder form of sclerostosis and is 
caused by a deletion downstream of this gene, with a consequent reduced sclerostin 
expression. SOST gene knock out mice don’t produce sclerostin and have a high bone mass, 
confirming the effect of this protein on bone mass and BMD. Besides the increase in bone 
mass and BMD taking place from sclerostin deficiency, there have been no reports of 
fractures in individuals with sclerosteosis or van Buchem disease. (Hamersma et al., 2003; 
Wergedal et al., 2003) 
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Sclerostin binds to low-density lipoprotein receptor-related protein (LRP) 5/6 and blocks 
Wnt-signaling, negatively regulating bone formation and in that way, inhibiting osteoblast 
differentiation, proliferation, and activity. (Baron & Rawadi 2007) Thus, the inhibition of 
sclerostin was thought to have therapeutic potential in treating human bone metabolism 
defects such as systemic bone loss, focal bone loss, fracture healing, and orthopedic 
procedures where increases in bone formation, bone mass, bone mineral density (BMD), and 
consequently bone strength, are sought-after. (Ott, 2005)  
5.2.1 Sclerostin inhibition 
Rats treated with a sclerostin antibody experience a reversal of estrogen deficiency induced 
bone loss at several skeletal sites. Additionally, an increase in bone mass and strength is 
observed in treated rats compared with controls. Similar results were observed in treated 
monkeys. In models of fracture healing in mice and rats, treatment with a sclerostin 
antibody increased bridging and bone strength at sites of fracture, resulting in enhanced 
bone healing compared with controls. (Padhi et al., 2011) 
AMG 785 is a high affinity immunoglobulin G2 (IgG2) monoclonal antibody generated by 
humanizing a mouse sclerostin monoclonal antibody that neutralizes sclerostin. The first-in-
human single-dose study in healthy men and postmenopausal women was performed to 
evaluate pharmacokinetics, pharmacodynamics, tolerability and safety of doses of 0.1, 0.3, 1, 
3, 5 or 10 mg/kg sub-cutaneus and 1 or 10 mg/kg intravenous of AMG 785. A total of 72 
subjects participated in the study and were followed for up to 85 days. Study product 
pharmacokinetics was nonlinear with dose. Dose-related increases in bone formation 
markers and decreases in bone resorption markers were observed. A small percentage of the 
patients developed anti-investigational product bodies but most of them were non-
neutralizing antibodies. The medication was well tolerated. (Padhi et al., 2011) A phase II 
study of 419 postmenopausal women with low BMD has been started to compare the 
efficacy of sclerostin neutralization with alendronate and teriparatide. (Rachner et al., 2011) 
Finally, a multicenter, phase IIa, randomized double-blind, placebo controlled, multi-dose 
study is ongoing to evaluate safety, tolerability, pharmacokinetics, and phamacodynamics 
of AMG 785 in postmenopausal women with low bone mass. In conclusion, anti sclerostin 
antibody treatment could be the most effective treatment for osteoporosis and bone defect 
related diseases. Even though, we will have to wait until all the ongoing and planned trials 
are over to analyze the data and have access to this kind of treatment.  
6. Conclusion 
During the last 10 years, new therapeutic agents have emerged among the pharmacological 
treatment options for osteoporosis. The newer options belong to new families with 
optimized mechanisms of action, allowing us to restore the lost bone mass quicker and more 
effectively than with the old medications. Nevertheless, one has to be conscious that all 
treatment options have specific indications and a wide range of adverse events, that have to 
be taken into consideration before making any decision. Moreover, it has to be remembered 
that most treatments for osteoporosis have to be given concomitantly with changes in 
lifestyle and/or calcium and vitamin D supplementation. New therapies are in development 
that probably will allow us to treat for a shorter time obtaining better results for our 
patients.  
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